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ABSTRACT 
Effect of Antimicrobials and Sodium Replacement Agents on 
 the Survival of Pathogenic Bacteria in Low Sodium 
 Low-Moisture Part-Skim (LMPS) 
 Mozzarella Cheese 
 
Tiffany M. J. Taylor 
 
 Recent increases in chronic cardiovascular diseases, such as 
hypertension, have put pressure on the food industry to reduce sodium levels.  
Dairy products, though full of vital nutrients, are perceived as being high in 
sodium.  However, the reduction of salt in dairy products could potentially alter 
the microbial stability, as well as cause unfavorable changes in flavor. In order to 
reduce the sodium level, while maintaining acceptable flavor and microbial 
stability, salt replacers and alternative antimicrobial agents may need to be 
introduced into the food matrix. To identify potential antimicrobials for use in 
reduced sodium dairy products, this study evaluated the efficacy of eight 
commercially available antimicrobials in TSA, milk agar, and cheese agar.  
Antimicrobials included MicroGard 100, MicroGard 430, Nisaplin, NovaGard 
CB1, Protect-M, PuraQ Verdad RV75, SEA-i F75 and VMY1P. Antimicrobials 
were also tested in combination with six commercial sodium reduction agents 
(potassium chloride, Puracal PP/USP, Purasal Hi Pure P Plus, PuraQ Verdad 
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NV10, SaltWise 0029 and SaltWise 1029) to if there were any interference with 
antimicrobial activity.  
Antimicrobials with and without sodium reduction agents were added to 
the agar systems, then a five-strain cocktail of Listeria monocytogenes, 
Salmonella or Escherichia coli O157:H7 was spread plated at three 
concentrations: 101, 102 and 104 CFU/plate.  Samples were then incubated at 
35°C and observed for growth after 24 and 48h.  SEA-i F75 was the most 
effective antimicrobial in each of the agars tested.  Additionally, no interactions 
were observed between SEA-i F75 and any of the sodium replacement agents.  
SEA-i F75 was selected for use in a final challenge study using six 
formulations of LMPS mozzarella cheese: regular sodium control cheese (1.7% 
NaCl, no antimicrobial added); low sodium control cheese (0.7% NaCl, no 
antimicrobial added); low sodium treated cheese (0.7% NaCl, treatment with 
SEA-i F75);  low sodium cheese with KCl as salt replacer (0.7% NaCl, 1.0% KCl, 
treatment with SEA-i F75); low sodium cheese with Alta 2345 as salt replacer 
(0.7% NaCl, 0.25% Alta 2345, treatment with SEA-i F75); and low sodium 
cheese with Salona as salt replacer (0.7% NaCl, 0.95% Salona, treatment with 
SEA-i F75).   
Fifteen gram cheese pieces from each formulation were dipped in an 
antimicrobial solution containing 0.25% SEA-i F75 then inoculated with L. 
monocytogenes, Salmonella, or E. coli O157:H7 at a target inoculum 
concentration of 102-103 CFU/g and incubated at either 4° or 12°C.  In all trials, 
over all formulations and temperatures tested, initial decreases in counts, 
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followed by organism recovery were observed.  Therefore, SEA-i F75 was not 
effective at reducing the counts of pathogenic bacteria in LMPS mozzarella 
cheese.  
Results from this study highlight the effect of the food matrix, and its 
components on antimicrobial efficacy.  Future research includes examining the 
effect of one of the other antimicrobials in LMPS mozzarella cheese.  
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1.0 Introduction: 
Dairy products have been implicated in foodborne outbreaks.  Of the 
4,438 foodborne outbreaks recorded form 1999 to 2008, 4.7 percent were linked 
to dairy products (DeWaal et al., 2012).  Outbreaks have been associated with 
several pathogenic organisms including E. coli O157:H7, Listeria monocytogenes 
and Salmonella.  Since pasteurization of milk eliminates vegetative pathogens, 
dairy-related outbreaks are typically linked to unpasteurized milk, improper 
pasteurization or post-pasteurization contamination (Reij and Aantrekker, 2004).  
Routes of post-pasteurization contamination include poor hygiene of food 
handlers, improper sanitation of processing equipment and insufficient air 
filtration in processing environments.  Enhancing sanitary practices in food 
processing facilities will decrease the likelihood of post-pasteurization 
contamination, but will not completely eliminate the risk.   
To prevent the growth or survival of pathogens, in case of contamination, 
many dairy products are formulated with ingredients that provide mild 
preservation, or microbial hurdles, which work in combination to control microbial 
spoilage (Leistner and Gorris, 1995).  These microbial hurdles may include low 
pH, high salt content, low water activity or the addition of sugar, nitrites or other 
preservatives.  In cheese, the common hurdles include the reduction in pH due to 
the addition of lactic acid bacteria and the addition of salt in the production of 
cheese.  Salt is added to food for its flavor as well as its antimicrobial properties 
(Guinee, 2004).  Adding salt to food lowers the water activity, reducing the water 
available for microorganisms and preventing their growth (Guraya et al., 1998; 
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Larson et al., 1993). While these factors can prevent the growth of pathogens 
and help to ensure microbial safety, high consumption of the key hurdle, salt, can 
have a negative effect on human health (Appel and Anderson, 2010). 
High salt intake has been linked with chronic heart disease and has been 
identified as one of the primary preventable factors in both obesity and 
hypertension (Sacks et al., 2001).  Cheese, though dense in nutrients such as 
protein, phosphorus and calcium, is also perceived as being high in sodium 
(Johnson et al., 2009).  Reducing the sodium in cheese, while conferring a 
benefit to the consumer, would also remove an important food safety hurdle and 
potentially alter the microbial stability of the product.  To address the potential of 
reduced microbial safety another hurdle, such as an antimicrobial, would need to 
be introduced into the food matrix. 
Limited research has been done to evaluate other commercially available 
antimicrobials that could potentially provide effective inhibition of pathogens in 
dairy products.  Previous research has primarily focused on the efficacy of 
bacteriocins, such as nisin, at inhibiting the growth of pathogens in agar and 
dairy products (Arques et al., 2008a; Arques et al., 2008b; Arques et al., 2011; 
Cleveland et al., 2001; Hammer et al., 1999; Oussalah et al., 2007a; Samelis et 
al., 2003; Stevens et al., 1991).  Additionally, studies about potential salt 
replacers have predominantly focused on the partial replacement of sodium 
chloride with potassium chloride (Bidlas and Lambert, 2008; Katsiari et al., 1997).  
Partial replacement with KCl can be effective at inhibiting pathogenic growth, but 
KCl may impart an unwanted bitter taste in dairy products.  Additional options for 
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preventing the growth of pathogens in the event of contamination need to be fully 
explored. 
This study aims to identify antimicrobials and compatible salt substitutes 
for use in the low sodium low-moisture part-skim (LMPS) mozzarella cheese.  
The objectives were to screen several commercially available antimicrobials to 
determine their potential for inhibiting the growth of Salmonella, L. 
monocytogenes, and E. coli O157:H7 in different agar systems, screen salt 
substitutes for potential antimicrobial activity, to look for interactions between 
antimicrobials and salt replacers and to perform a final challenge study with a 
suitable antimicrobial in low sodium LMPS mozzarella cheese.   
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2.0 Literature Review 
 
2.1 Low-Moisture Part-Skim Mozzarella Cheese 
 
2.1.1 Cheese Consumption in the US  
Cheese consumption is currently on the rise in the United States. Over the 
last twenty years, average cheese consumption has nearly tripled (Buzby, 2005).  
Mozzarella cheese, mostly low-moisture part-skim (LMPS) mozzarella, has 
recently overtaken cheddar as the most popular cheese in the US.  In 2003, 
consumption of mozzarella averaged 9.6 pounds per person (Buzby, 2005).  The 
popularity of LMPS mozzarella cheese is largely attributed to its wide use in 
American-style pizza and the manufacture of string cheese (Fuquay et al., 2011).  
The increase in cheese consumption increases the need for dairy manufacturers 
to produce a safe product.  Since a large portion of mozzarella consumers are 
from a susceptible population, children and the elderly, the risk of developing 
food borne illness in the case of pathogenic contamination is high.  
 
2.1.2 Cheese Manufacture and Composition 
Cheese is defined as a curd of milk solids produced by the coagulation of 
casein and the trapping of milk fat in the coagulum (Fernandes, 2009).  LMPS 
mozzarella is made on a large scale and initially manufactured similarly to other 
semihard cheeses (Figure 2.1).  First, pasteurized milk is added to a cheese vat.  
 5 
 
Milk is then standardized to a casein-to-fat ratio of 1.2 through either the removal 
of cream or by adding extra solids through the addition of liquid skim milk 
concentrate or nonfat dry milk (NFDM) powder.  Milk is then acidified to a pH of 
5.0 – 5.3 through either chemical (direct) acidification or biological (culture) 
acidification methods.  In direct acidification, organic acids, such as citric acid or 
acetic acid, are used to decrease the pH of the milk.  Culture acidification utilizes 
lactic acid bacteria to produce lactic acid from the milk lactose, eventually 
decreasing the milk pH.  Direct acidification, though more easily controllable, 
does not contribute to ripening or flavor development, thus culture acidification, 
using thermophilic cultures, is typically utilized in LMPS mozzarella (Jana and 
Mandal, 2011).  
Once the milk has reached the target pH, rennet, a milk-clotting enzyme, 
is added to coagulate the milk.  After the coagulum forms, it is cut, and the curd 
and whey are stirred and heated from 35°C to 40°C.  When the pH of the curd 
reaches 6.2–6.3, the whey is drained and the curd is dry stirred to allow for more 
complete acidification and syneresis of the whey.  At a pH of 5.3, the curd is 
removed from the vat, put into the cooker/stretcher then extruded, which aligns 
the cheese fibers into parallel strands, giving the cheese its characteristic elastic, 
stringy texture.  After extrusion, the cheese is brine-salted, molded into the 
desired form, then individually vacuum packaged.   
LMPS mozzarella cheese standards of identity include having a minimum 
milkfat content of greater than 30 percent, but no more than 45 percent, and a 
moisture content of more than 45 percent but less than 52 percent 
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(21CFR133.156; 21CFR133.157).  Final Mozzarella cheese is primarily 
composed of water, protein and fat (Table 2.1). 
 
 
Figure 2.1 Flow chart of the manufacture of mozzarella cheese. 
Source: Jana, A. H., & Mandal, P. K. (2011). Manufacturing and Quality of Mozzarella Cheese: A Review. 
International Journal of Dairy Science, 6(4), 199-226. 
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Table 2.1 Typical composition of Mozzarella cheese in the United States.  
Component  
Moisture (%) 45 – 52 
Protein (%) 20 
Fat (%) 30 – 45 
Lactose (%) 1.5 
Ash (%) 2 – 4  
Salt (NaCl) 546 – 814 mg/serving 
 
Source: Agarwal, S., McCoy, D., Graves, W., Gerard, P. D., & Clark, S. (2011). Sodium content in retail 
Cheddar, Mozzarella, and process cheeses varies considerably in the United States. [Article]. Journal of 
Dairy Science, 94(3), 1605-1615; Jana, A. H., & Mandal, P. K. (2011). Manufacturing and Quality of 
Mozzarella Cheese: A Review. International Journal of Dairy Science, 6(4), 199-226.  
 
2.1.3 Consumer Health Concerns with Cheese Products  
Consumers have recently become concerned with levels of salt intake.  
this increased concern has encouraged some consumers to decrease their 
intake of processed foods.  Processed foods typically contain high levels of salt 
and, since cheese is considered a processed food, it is perceived as being high 
in sodium.  Average salt content of cheese ranges from 0.5-0.7% in acid curd 
cheeses to 4-6% in pickled cheeses (Guinee, 2004).  Though the recommended 
daily intake of sodium is less than 5.8 g of salt, in the US daily salt intake 
averages 10.4 g for men and 7.3 g for women (Bibbins-Domingo et al., 2010).  
Excessive dietary sodium has been shown to have detrimental effects on 
cardiovascular health; there is a strong causal relationship between high dietary 
salt intake and hypertension (Kornitzer et al., 1999; Mohan and Campbell, 2009).  
Hypertension is the major cause of cardiovascular disease, ahead of smoking 
and raised cholesterol (He et al., 2009; Kung et al., 2008).  Increased 
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hypertension prevalence reflects a continuing need for reducing sodium intake 
through health policy and individual practice (Fields et al., 2004).  
It has been estimated that a national effort to reduce salt by 3 g a day 
could reduce the annual number of new cases of coronary heart disease by 
60,000 to 120,000, stroke by 32,000 to 66,000, myocardial infraction by 54,000 to 
90,000 and annual deaths by 44,000 to 92,000; reduction of dietary sodium could 
also potentially save $10 billion to $24 billion in health care costs annually (Appel 
and Anderson, 2010).  Population intervention studies that successfully reduced 
salt intake observed a decrease in blood pressure (He and MacGregor, 2009). 
Reducing consumer salt intake in Japan from an average of 13.5 to 12.1 g/day 
was associated with an 80% reduction in stroke mortality, as well as a decrease 
in blood pressure in both adults and children.  Earlier research done by Sacks, et 
al. (2001), showed that reducing the sodium chloride content of typical diets in 
the US by 140 mmol per day led to decreases in blood pressure.  Decreasing the 
incidence of hypertension through salt reduction would be highly effective and 
inexpensive and could be as beneficial as interventions aimed at smoking 
cessation and weight reduction (Ferrante et al., 2011).  
The two main ways to decrease dietary salt intake are by processors 
reducing levels of salt in processed and prepared foods or consumers selecting 
and preparing food with little or no salt.  Since roughly 75% of dietary salt comes 
from processed foods, the most effective way to decrease salt intake would be 
through the reduction of added sodium during processing (Appel and Anderson, 
2010; Bibbins-Domingo et al., 2010).  However, since salt plays many functional 
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roles in processed foods, several issues arise when reducing sodium in 
processed foods, including unfavorable changes to product flavor and decreased 
shelf life stability.  
 
2.2 Salt Reduction Challenges 
 
2.2.1 Importance of Salt in Cheese 
Salt, in the form of NaCl, plays several direct and indirect roles in cheese. 
Salt helps to enhance flavor by controlling the metabolism of the starter bacteria 
and the activity of enzymes, as well as providing consumers with the 
characteristic salty taste in cheese (Johnson et al., 2009).  Fermentation 
processes rely on salt to inhibit the proliferation of undesirable microorganisms 
while permitting the growth of starter bacteria and native microflora (Taormina, 
2010).  Salt also affects the level of proteolysis by controlling the rate and extent 
of fermentation.  Reducing the concentration of salt in cheese can cause 
abnormal fermentations, resulting in increases in proteolysis, acidity and 
bitterness, as well as decreases in firmness and saltiness (Agarwal et al., 2011; 
Katsiari et al., 1997). 
Salt also acts as a preservative in cheese; it has some of the most 
effective antimicrobial properties against foodborne pathogens and spoilage 
organisms (Taormina, 2010).  Salt is able to stop or slow the growth of 
microorganisms through the reduction in water activity, as well as disrupting 
transfer through cellular membranes (McMahon, 2010).  Removing salt from 
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cheese, thereby raising the water activity, could diminish food safety and allow 
pathogens to grow or persist during processing (Taormina, 2010).  
 
2.2.2 Microbial Safety 
 
2.2.2.1 Sources of Contamination  
Dairy product stability is a result of intrinsic properties, such as pH, aw and 
salt, combined with pasteurization for microbial preservation and safety.  In the 
absence of refrigeration or a key microbial hurdle, such as salt, the composition 
of dairy products can provide a favorable environment for growth.  The majority 
of dairy products are ready-to-eat (RTE) and their composition provides a 
favorable physical and chemical environment for the growth and propagation of a 
broad spectrum of microorganisms (Hotchkiss et al., 2006).  
There are several routes through which microorganisms can contaminate 
dairy foods: a lack of pasteurization, inadequate pasteurization or post-
pasteurization microbial recontamination (Hotchkiss et al., 2006).   
 
2.2.2.1.1 Unpasteurized Cheese Products.  Recently, consumer 
interests have shifted towards minimally processed foods, including 
unpasteurized cheese products.  The consumption of unpasteurized milk carries 
with it some health concerns, as it can easily be contaminated with pathogens at 
the farm and processing levels.  Mastitis, an infection of the udder of the cow, is 
one of the pathways by which pathogens are shed into milk.  Staphylococcus 
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aureus is one of the major causes of mastitis in dairy cows (Fuquay et al., 2011).  
Infections can cause up to 108 CFU/ml of the organism to be shed into milk. 
Salmonella spp., Listeria monocytogenes and E. coli O157:H7, though 
uncommon, have also been found to cause mastitis or colonize udders (Kousta 
et al., 2010).  Improper cleaning of udders, or milking machines, can lead to the 
shedding excretion of pathogens into milk. 
Several other factors at dairy farms influence the prevalence of pathogens 
in raw milk, including the farm size, number of animals on the farm and the 
season (Kousta et al., 2010).  Using raw milk contaminated with high levels of 
pathogenic bacteria to produce cheese could potentially result in contaminated 
cheese.  Though cheese produced from unpasteurized milk is aged for 60 days 
prior to consumption, several studies have shown that the aging requirement is 
not sufficient enough to eliminate the presence of pathogens (D'Amico et al., 
2010; Maher et al., 2001; Schlesser et al., 2006).  
 
2.2.2.1.2 Recontamination of Cheese Products.  Microorganisms can 
also contaminate dairy products through recontamination after processing. WHO 
(1995), determined that almost 25 percent of foodborne outbreaks could be 
traced back to recontamination (Reij and Aantrekker, 2004).  There are several 
routes of recontamination, including cross contamination between raw and 
processed foods, the introduction of pathogens into the processing environment, 
and the lack of hygienic practices during the processing and production by dairy 
workers.  Additionally, contaminated raw materials or ingredients could 
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inadvertently be added to finished products through the contamination of food 
contact surfaces or processing equipment.  Ineffective or inadequate cleaning 
and disinfection of contaminated food contact surfaces would lead to 
recontamination.   
L. monocytogenes presents the largest challenge to the safety of dairy 
foods due to its ability to withstand low pH and refrigeration conditions.  
Preventing L. monocytogenes from establishing a niche and growing in the 
processing environment is a major focus of dairy facilities (Tompkin et al., 1999).  
Food processing equipment has several niches, or harborage sites, on food 
contact and non-food contact surfaces, that are difficult to clean and frequently 
missed during regular cleanings (Grinstead and Cutter, 2007).  Without effective 
cleaning, L. monocytogenes is able to grow and form biofilms.  The formation of 
biofilms by L. monocytogenes makes it more difficult to kill with sanitizers and 
disinfectants due to the protective film or slime layer associated with the biofilm 
(Grinstead and Cutter, 2007); this factor enhances the resistance of L. 
monocytogenes to cleaning and sanitation, thereby promoting its transmission to 
food (Adetunji and Adegoke, 2008).  
In addition to processing equipment, cheese can be contaminated via 
cheese brines (Kousta et al., 2010).  Commercial cheese brines are often used 
repeatedly and may be pasteurized infrequently or not at all.  Brines are 
contaminated through cheese made from unpasteurized milk or by the 
unintentional addition of unpasteurized milk to the brine.  Once the brine is 
contaminated, microorganisms can be spread to cheeses in other batches during 
 13 
 
brining. Salmonella, E. coli O157:H7 and L. monocytogenes have been shown to 
survive for greater than seven days in cheese brines (Ingham et al., 2000; Larson 
et al., 1999).  
The potential risk for the recontamination of dairy products in the 
processing environment highlights the importance of antimicrobial hurdles in the 
formulation.  Formulating product with intrinsic antimicrobial properties would 
prevent the growth or survival of the bacteria in the case of pathogenic 
contamination.  
 
2.2.2.2 Pathogen Growth and Survival in Cheese 
Cheeses, as they are naturally formulated, will support the survival and/or 
growth of pathogens if they are introduced via the raw milk or the processing 
environment.  Pathogens are ubiquitous in nature and several factors, including 
the ability to withstand lower pH values and refrigerated temperatures, contribute 
to their growth and survival in cheese (Table 2.2).  L. monocytogenes and some 
strains of Salmonella spp. have the ability to grow at refrigeration temperatures.  
E. coli O157:H7 and Salmonella have the capability of growing at pH values as 
low as 4.5.  The growth and survival patterns of E. coli O157:H7, L. 
monocytogenes, Salmonella spp. and Staph. aureus have been well studied in 
cheese.  
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Table 2.2 Growth characteristics of pathogenic microorganisms1. 
Organism 
Growth 
Temperature Range 
Optimum Growth 
Temperature Range 
Lowest pH 
Tolerated for 
Growth 
E. coli O157:H7 10 – 45°C 30 – 42°C 4.5 
L. monocytogenes  1 – 44°C 30 – 37°C 5.0 
Salmonella spp.  5 – 46°C 35 – 37°C 4.5 
Staph. aureus   7 – 48°C 20 – 37°C 4.8 
1
Source: Ray, B., & Bhunia, A. (2008). Fundamental Food Microbiology (4th ed.). Boca Raton, FL: CRC 
Press. 
 
2.2.2.2.1 E. coli O157:H7.  E. coli O157:H7 cells can persist and 
proliferate during the manufacture and storage of a variety of cheese products.  
Reitsma & Henning (1996) showed that, in cheddar cheese, E. coli O157:H7 
could survive the manufacturing process, as well as the minimum 60 day curing 
period at a temperature greater than or equal to 2°C.  The organism was also 
able to survive the manufacturing process of mozzarella despite a stretching 
temperature of 70°C (Spano et al., 2003).  Cells have survived and grown during 
the manufacture and storage of paneer, an Indian cheese, at 4°, 8° and 28°C 
(Wahi et al., 2006).  By the end of the 48 h storage, E. coli O157:H7 counts had 
increased by over 1 log CFU/g over all temperatures tested.  
During cold storage, E. coli O157:H7 will not grow.  However, the 
organism can survive and, with its low infective dose, potentially cause illness.  
Another study showed that E. coli O157:H7 persisted in soft cheese samples 
stored at 8°C during a two month incubation and grew when incubated at 10° and 
30°C (Kasrazadeh and Genigeorgis, 1995).  E. coli O157:H7 has also been 
shown to survive in an acidified dairy food.  The organism was able to grow at 
 15 
 
12°C in dairy products at pH values of 5 and 5.4, as well as survive at pH 4.7 
with up to 4% salt concentration (Guraya et al., 1998).  Additionally, cells could 
survive in white cheese (0.5% NaCl) at a pH of 3.9 for over 20 days when stored 
at 7°C.  
 
2.2.2.2.2. Salmonella spp.  Several studies have evaluated the behavior 
of Salmonella in cheese.  In brie cheese, Salmonella counts increased during 
storage at 20°C and, though counts declined slowly at 4° and 8°C, the organism 
was present in the cheese for up to 35 days (Little and Knochel, 1994).  
Salmonella was introduced into regular and low salt (0.7%) cheddar cheese as a 
post-aging contaminant (Shrestha et al., 2011b).  In regular cheddar cheese, 
Salmonella was undetectable by plating after 30, 30 and 20 days when incubated 
at 4°, 10° and 21°C, respectively.  However, when artificially inoculated into low 
salt cheddar cheese, Salmonella was present throughout incubation at 4°, 10° 
and 21°C for up to 90, 90 and 30 days, respectively.  
Another study evaluated the behavior of Salmonella during the 
manufacture of cheddar cheese.  Salmonella was introduced at one of several 
stages of cheddar cheese manufacture: in the raw milk, immediately after 
pasteurization, mixed with lactic starter before adding or via utensils (White and 
Custer, 1976).  Salmonella survived manufacture and storage of the cheddar 
cheese at 4.5°C for at least 5 months regardless of the pathogen addition stage.  
Additionally, Salmonella has been shown to survive the manufacture and 
ripening of raw milk cheeses.  In herby and montasio cheeses, traditionally made 
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from raw milk, Salmonella survived when ripened for 90 days at 4°C (Alemdar 
and Agaoglu, 2010; Stecchini et al., 1991).  
 
 
2.2.2.2.3 Staphylococcus aureus.  Staph. aureus is a concern in the 
dairy industry due to the organism’s growth characteristics and ecological niche.  
Staph. aureus can be found in the nostrils, and on the hair and skin of humans, 
increasing the likelihood of its introduction to foods during processing.  
Additionally, the organism has been shown to grow at pH values as low as 4.2 
and NaCl concentrations up to 15%, allowing it to persist in a  variety of 
fermented foods, such as cheese (Reference).    
Previous research of the behavior of Staph. aureus in different cheeses 
has displayed the organism’s survival and growth during manufacture, ripening 
and storage.  A semihard, uncooked, raw milk cheese supported the survival of 
Staph. aureus during manufacture (Delbes et al., 2006).  After manufacture, 
counts of Staph. aureus ranged from 2.82 to 6.84 log CFU/g. Staph. aureus 
survived ripening at 12°C in a montasio cheese and cheeses manufactured with 
commercial lactic cultures for 90, 60 and 30 days, respectively (Arques et al., 
2005; Rodriguez et al., 2005; Stecchini et al., 1991).  During a 12 day storage 
period at 10°C Staph. aureus grew over 4 log CFU/g in cuajada, a semisolid 
dairy product, (Arques et. al, 2008a).  Staph. aureus was introduced into 
Machego cheese, manufactured from raw ewes’ milk and ripened for 60 days at 
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10°C (Nunez et al., 1988).  The organism survived the entire ripening period, but 
staphylococcal enterotoxins were not detected in any of the samples.   
The growth and survival of Staph. aureus has been researched in several 
fermented products, however, in order to cause illness, the organism must be 
able to grow and produce toxin in the food matrix.  Staph. aureus  has been 
shown to produce toxin in a cheese matrix.  The organism was introduced in a 
Camembert-type cheese, produced from raw goats’ milk, at several different 
inoculum levels (Meyrand et al., 1998).  Results showed that Staph. aureus grew 
by 2—3 log CFU/g and that enterotoxin was detected during the 41 day storage 
at 4°C.  
 
2.2.2.2.4 Listeria monocytogenes.  L. monocytogenes is arguably the 
most challenging pathogen in the dairy industry.  The organism is able to 
withstand many of the hurdles intrinsic to dairy products including high salt levels 
and refrigeration temperatures.  If introduced in the processing environment, L. 
monocytogenes can persist through the formation of sanitizer resistant biofilms, 
which can potentially contaminate final product.  Additionally, L. monocytogenes 
is psychrotrophic, allowing it to grow at refrigeration temperatures.   
L. monocytogenes survival and growth in dairy products is well 
documented.  L. monocytogenes was able to survive in Greek-style Galotyri 
cheese for 28 days at 4°C and up to 14 days at 12°C (Rogga et al., 2005).  L. 
monocytogenes survived for 90, 90 and 30 days in cheddar cheese when 
incubated at 4°, 10° and 21°C, respectively (Shrestha et al., 2011a).  No 
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decrease in L. monocytogenes counts was observed over the 12 day incubation 
at 10°C when the organism was artificially inoculated into cuajada, a semisolid 
dairy product (Arques et al., 2008a). 
Studies have shown that L. monocytogenes will grow rapidly when 
cheeses are formulated with reductions in microbial hurdles.  Queso fresco 
cheese is associated with high risk of L. monocytogenes contamination due to its 
low salt content, near neutral pH (6.0 - 6.5) and high moisture content.  If L. 
monocytogenes were to contaminate queso fresco cheese, the lack of microbial 
hurdles would permit rapid growth, even at refrigeration temperatures.  The 
concentration of L. monocytogenes increased by 4-5 log CFU/g after 28–35 days 
of incubation at 4°C in queso fresco cheese (Leggett et al., 2012; Soni et al., 
2012; Soni et al., 2010).  When the incubation temperature was increased to 
10°C, the same log increase was observed after only 10 days.    
 
Studies listed above have shown that pathogens can survive the 
manufacture, ripening and storage of different cheeses.   Additionally, inoculated 
cheeses formulated with reductions in any of the microbial hurdles (i.e. lower salt 
content, increased pH) displayed more rapid growth rates.  These results 
highlight the importance substituting removed or reduces microbial hurdles in 
order to maintain microbial stability.  
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2.2.2.3 Cheese-Related Outbreaks 
 The consumption of cheeses contaminated with pathogens and their 
toxins can cause serious foodborne illness problems, threatening human health 
and causing large economic losses.  Of the 209 dairy-related outbreaks reported 
from 1999 to 2008, almost 30% involved cheese (DeWaal et al., 2012).  Cheese 
has been the vehicle for several pathogenic outbreaks involving E. coli O157:H7, 
Salmonella spp., Staphylococcus aureus and Listeria monocytogenes.  In the 
majority of outbreak cases listed below, a microbial hurdle was either reduced or 
removed, permitting the growth of the pathogen and causing illness.  
 
2.2.2.3.1 E. coli O157:H7. Outbreaks of E. coli O157:H7 in cheese have 
largely been associated with the consumption of unpasteurized products or final 
products that have contaminated with unpasteurized milk.  Removing the thermal 
processing hurdle put the final product at greater risk for contamination.  Thirty-
eight people were affected by an E. coli O157:H7 outbreak linked to 
unpasteurized Bravo Farms Dutch-style Gouda cheese (CDC, 2010).  Fifteen 
people were hospitalized and one case of HUS was reported, but there were no 
deaths.  The exact cause of this outbreak is unknown.  The FDA investigation 
revealed that there were no other implicated cheese products and it was not 
clear how long cheese had been aged.  
In 1998, pasteurized fresh cheese curds were implicated in an E. coli 
O157:H7 outbreak (CDC, 1998).  Fifty-five laboratory cases were identified and 
twenty-five people were hospitalized, but there were no reported fatalities.  The 
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outbreak was traced back to cheese vats that had been used to produce raw milk 
cheeses prior to the production of pasteurized fresh cheese curds. 
 In July 2010, Sally Jackson cheeses were implicated in a multistate E. 
coli O157:H7 outbreak (Rothschild, 2010).  Eight people were affected and two 
were hospitalized.  The outbreak strain was isolated from the production facility 
and, while the exact cause of the outbreak is unknown, processing conditions 
could have led to unpasteurized milk coming into contact with final cheese 
product.  Preventing E. coli O157:H7 contamination is of great concern in the 
food industry due to the low infectious dose of the organism;  no growth is 
necessary in order to cause illness.  
   
2.2.2.3.2 Salmonella spp.  Salmonella has also been associated with 
outbreaks related to unpasteurized cheeses.  A Salmonella Typhimurium 
outbreak was linked to raw milk and cheese consumption in Pennsylvania (CDC, 
2007).  A total of twenty-nine cases were identified; two were hospitalized, but no 
deaths were reported.  Inspections of the implicated dairy revealed improper 
cleaning of milking equipment and insufficient supervision of workers, along with 
bird and rodent infestation.  In another outbreak, raw milk queso fresco cheese 
contaminated with Salmonella Typhimurium sickened fifty-four people and 
caused five hospitalizations (Villar and Macek, 1997).  Also, unpasteurized 
Mexican-style aged cheese contaminated with Salmonella enterica serotype 
Newport affected eighty-five people and caused thirty-six hospitalizations from 
March 2006 to April 2007(CDC, 2008).  Pasteurization is the first major hurdle in 
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the prevention of illness related to cheese products.  Removing that hurdle made 
the product more susceptible to Salmonella contamination and more likely to 
cause food borne illness.  However, Salmonella has also been the cause of 
outbreaks in pasteurized cheese.  
Consumption of contaminated Mozzarella cheese resulted in an outbreak 
of S. javiana and S. oranienberg infections that affected 139 people (Hedberg et 
al., 1992).  The outbreak resulted from contaminated mozzarella that was 
produced at a manufacturing plant, and then sent to four separate processing 
plants for shredding.  Contamination of other cheese products occurred at the 
processing plants during shredding.  The presence of Salmonella in a 
pasteurized cheese product at high enough levels to cause illness emphasizes 
the importance of the microbial stability of the product formulation.  In order to 
produce a safe product, sufficient microbial hurdles are necessary to reduce 
microbial populations in the case of pathogenic contamination.  
 
2.2.2.3.3 Staphylococcus aureus.  Two separate outbreaks of Staph. 
aureus have been linked to dishes containing cheese.  In 2007, fourteen people 
fell ill from Staph. aureus isolated from multiple foods at a church and a private 
home.  Another outbreak affecting seventeen people resulted from an Italian 
restaurant; a cannelloni, containing cheese and chicken, tested positive for 
Staph. aureus (Anderson et al., 2009).  It was found that the dish was not kept at 
safe food handling temperatures.   Again, the ability of Staph. aureus to survive 
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and grow in fermented foods, as well as its widespread presence in human 
hosts, increase the likelihood of its presence in cheeses.  
 
2.2.2.3.4 Listeria monocytogenes.  L. monocytogenes outbreaks are of 
extreme concern to the dairy industry.  The organism affects a very sensitive 
population, has a high mortality rate and is often found in the processing 
environment.  L. monocytogenes has been associated with both pasteurized and 
unpasteurized cheese products. Two of the largest cases of listeriosis reported 
were caused by pasteurized dairy products in the early 1980s.  
In 1983, a listeriosis outbreak was associated with the consumption of 
pasteurized milk (Fleming et al., 1985).  A total of forty-nine people were affected 
and nineteen deaths were reported.  In 1985, 142 cases of L. monocytogenes 
infection were identified in California; twenty-eight deaths were recorded (CDC, 
1985).  The source of the infection was traced back to Mexican-style cheeses 
produced by Jalisco Products, Inc.  Positive cheese samples all had different 
expiration dates, suggesting a continuing problem with the manufacturer’s 
cheese products.  An investigation of the plant showed that the cheese was 
commonly contaminated by with unpasteurized milk.  
In 2000, L. monocytogenes affected thirteen people in North Carolina 
(MacDonald et al., 2005); there were no deaths reported.  The outbreak was 
attributed to the consumption of queso fresco cheese made from raw milk and 
sold by a door-to-door vendor.  Another outbreak linked to Mexican-style asadero 
cheese, made from pasteurized milk, was reported in January of 2009; eight 
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cases in five states were identified, but no fatalities were reported (Jackson et al., 
2011).   A vat gasket was identified as a potential source of contamination of 
pasteurized milk.  However, cheese that was produced after the gasket was 
removed continued to test positive for L. monocytogenes.   The sustained 
presence of the organism indicated more intensive cleaning issues within the 
plant as well as gasket maintenance issues.  
 Preventing L. monocytogenes from entering and establishing itself in the 
processing environment is the first step to preventing contamination of finished 
products.  Additionally, plant sanitation and sanitary design of equipment play a 
role in the safety of cheeses.  However, the importance of product formulation 
cannot be overlooked.  Queso fresco and other Mexican-style cheeses are 
frequently associated with pathogenic contamination due to the lack of microbial 
hurdles; these cheeses are often formulated with reduced salt content and higher 
pH values.  By increasing the pH or substituting the removed salt in order to 
maintain microbial stability, these products could potentially reduce the risk of 
contamination.  
 
2.3 Formulating Reduced Salt Products 
 
2.3.1 Salt Replacers 
Reducing salt in cheese affects flavor and shelf stability as well as the 
enzymatic processes that help develop the texture.  In order to successfully 
achieve a reduction in sodium, a salt replacer that addresses the functional and 
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sensory qualities of the cheese needs to be added. However, the research of 
sodium replacement agents in cheese is limited, mainly focusing on cheddar and 
feta cheeses.  In a study aimed at finding a suitable replacement for salt in 
cheddar cheese, cheese was produced using NaCl alone or in combination with 
either CaCl2, KCl or MgCl2, then evaluated by a trained sensory panel (Grummer 
et al., 2012).  Sensory scores of cheddar cheeses made with a combination of 
NaCl and KCl were most similar to cheeses made with NaCl alone.  Cheeses 
produced with MgCl2 and CaCl2 were positively correlated with bitter, metallic, 
earthy, unclean and soapy flavors.   
KCl is one of the most widely used salt replacers in the food industry and 
is generally used to reduce sodium concentrations by 25-50% (Durack et al., 
2008).  Studies have shown that, in addition to KCl maintaining sensory qualities 
of cheese, using it to replace NaCl does not affect proteolysis or lipolysis in 
cheese (Katsiari et al., 2000a; Katsiari et al., 2001a; Katsiari et al., 1997; Katsiari 
et al., 2000b; Katsiari et al., 2001b).  NaCl and KCl were used in different ratios 
(NaCl contorl, 3:1 NaCl: KCl, 1:1 NaCl: KCl) for brining or dry salting feta and 
Kefalograviera, a traditional hard Greek cheese.   After 180 days storage, the 
partial replacement of NaCl by KCl did not influence the extent and 
characteristics of proteolysis or lipolysis in feta or Kefalograviera after 240 and 
180 days of storage, respectively.  
Although previous work has shown that partial replacement with KCl 
maintains acceptable flavor, similar studies have not been performed in 
mozzarella. Intrinsic differences in the formulations could lead to the 
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development of undesirable flavors in mozzarella if formulated with KCl.  In 
addition to replacing the flavor in cheeses, the issue of microbial safety needs to 
be addressed in cheeses with reduced salts.  
 
2.3.2 Antimicrobial Compounds 
 
2.3.2.1 Potassium Chloride 
In addition to functioning as a sodium replacement agent, KCl has been 
studied for its potential antimicrobial efficacy.  KCl functions by reducing the 
water activity, limiting the available water for microorganism use for metabolic 
functions and growth.  KCl was just as effective as NaCl in terms of inactivation 
and inhibition of the growth of Aeromas hydrophilia, Enterobacter sakazakii, 
Staphylococcus aureus, Yersinia enterocolitica and Shigella flexneri in TSB when 
added in the same concentrations, or in concentrations that result in the same 
water activity of the medium (Bidlas and Lambert, 2008).  NaCl, KCl and a 55/45 
KCl:NaCl ratio were added to rennet whey and challenged against S. heidelberg 
and L. monocytogenes (Larson et al., 1993).  Alone, or in a 55:45 ratio with NaCl, 
KCl was shown to be just as effective at inhibiting the growth of the organisms as 
NaCl alone, even though there were no significant differences in water activity.  
 
2.3.2.2 Bacteriocins 
 Bacteriocins are a group of bioactive peptides, produced by several 
strains of lactic acid bacteria (LAB) and some propionic bacteria.  Bacteriocins 
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are widely used in foods for their antimicrobial activity against closely related 
organisms.  Bacteriocins can be added to foods in one of two ways: 
bacteriocinogenic cultures can be added to the food or used as starter cultures, 
or food can be supplemented directly with bacteriocins, specifically for the 
purpose of inhibiting the growth of pathogenic or spoilage microorganisms.  
Antimicrobial activity of bacteriocins is based on the disruption of the integrity of 
the cytoplasmic membrane, increasing its permeability (Montville and Chikindas, 
2007).  This increase in permeability allows the nonspecific influx of ions into the 
cell. Cells then have to expend energy, in the form of ATP, either to expel the 
additional ions or to regenerate the proton motive force.  The ultimate loss of 
ATP, due to changes in permeability, leads to microbial growth inhibition and cell 
death.  
Gram-positive organisms are generally more sensitive to the antimicrobial 
activity of bacteriocins than are Gram-negative organisms.  Gram-negative 
bacteria have an outer membrane that provides resistance to bacteriocins; 
however, destabilizing the cell surface by physical (freezing or heating) or 
chemical (chelating agents or high hydrostatic pressure) stresses can render the 
bacteria sensitive to the action of these antimicrobials (Montville and Chikindas, 
2007; Ray and Bhunia, 2008).  
Bacteriocins are separated into two groups based on their molecular 
structures.  Class I bacteriocins contain lanthionine rings, and therefore are also 
known as lantibiotics.  Nisin, a lantibiotic produced by Lactococcus lactis subsp. 
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lactis, is one of the most well characterized bacteriocins used in the food 
industry.    
The antimicrobial activity of nisin is dependent upon the incubation 
temperature and pH of the product; in general, nisin is most effective at lower 
incubation temperatures and in acidic environments (Montville and Chikindas, 
2007).  Nisin has varying degrees of efficacy against Gram-negative and Gram-
positive organisms in dairy products.  Nisin exhibited a bacteriostatic effect 
against Staph. aureus and Salmonella enterica in skim milk refrigerated at 8°C 
for 12 days (Arques et al., 2008b; Arques et al., 2011).  Conversely, nisin could 
not inhibit the growth of E. coli O157:H7 or L. monocytogenes in skim milk during 
incubation at 8°C; the organisms grew by 2 log CFU/ml and 4.5 log CFU/ml, 
respectively, by the end of incubation.  
Nisin can work synergistically with other antimicrobials, bacteriocins or 
chelating agents to inhibit growth or induce death.  When combined with 
lactoperoxidase, nisin exhibited bactericidal effects against L. monoctyogenes in 
Cuajada, a semisolid dairy product (Arques et al., 2008a).  L. monocytogenes 
counts had decreased 4 logs to below detectable levels (detection limit of 1 
CFU/ml) after 12 days of incubation at 10°C.  In a broth system, 
ethylenetriaminetetraacetic acid (EDTA) combined with nisin effectively 
decreased the counts of Salmonella spp. and E. coli O157:H7 when incubated at 
37°C for 24 h (Stevens et al., 1991).  Within 60 minutes of treatment, Salmonella 
counts had decreased by 3.2–5.0 log CFU/ml while E. coli O157:H7 counts had 
decreased by 6.9 logs.  
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The activity of nisin is also highly dependent on the concentration of the 
bacteriocin; once all of the nisin has been bound, there is none left to further 
inhibit growth.  The addition of nisin, at a concentration of 100 IU/g, initially 
decreased the count of L. monocytogenes in artificially inoculated skim milk 
incubated at 4°C for 24 h (Zapico et al., 1998).  However, after the initial 
decrease, L. monocytogenes grew by 5 logs CFU/g by the end of incubation.  
Similarly, in artificially inoculated Anthotyros, a Greek whey cheese, nisin initially 
decreased the concentration of L. monocytogenes by 1 log CFU/g (Samelis et 
al., 2003).  However, after initial reduction, the organism grew more than 4 logs 
over a 45 day incubation at 4°C.  When the concentration of nisin was increased 
to 500 IU/g, nisin immediately reduced the concentration of L. monocytogenes by 
2 log CFU/g in Anthotyros and prevented the growth of the organism for up to 45 
days at 4°C.  
Bacteriocins that do not contain lanthionine are grouped in Class II.  Class 
II includes pediocin-like bacteriocins.  Pediocins are inactive against bacterial 
spores, but are capable of inhibiting the growth of vegetative cells.  When used in 
cheese production, pediocin-producing cultures have shown bactericidal activity 
against Staph. aureus, E. coli O157:H7 and L. monocytogenes during cheese 
ripening (Rodriguez et al., 2005).  Cheese was manufactured from milk artificially 
inoculated with the pathogenic organisms as well as the pediocin-producing 
strains.  After 30 days of ripening, counts of L. monocytogenes, Staph. aureus 
and E. coli O157:H7 had decreased by 2.97, 0.98 and 0.84 log CFU/g, 
respectively.  
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2.3.2.3 Organic Acids 
 Organic acids can be added to foods to inhibit microbial growth.  
Antimicrobial effectiveness of organic acids is related to pH and the acid 
dissociation constant, or pKa.  The pKa is the point at which 50% of the acid is in 
the undissociated form.  Generally, the undissociated form of the acid is 
responsible for the antimicrobial effectiveness of organic acids; organic acids are 
more effective when the majority of the acid is in the undissociated form or when 
the pH < pKa.  In the undissociated form, organic acids are able to penetrate the 
cell membrane.  Once inside the cytoplasm, the acids dissociate and generate 
protons.  These protons acidify the cytoplasm and must be expelled to the 
exterior in order to maintain a near neutral internal pH.  Transporting protons 
requires energy, in the form of ATP and the expulsion of protons eventually 
results in the depletion of cellular energy (Davidson and Taylor, 2007; Ricke, 
2003).  Acetic, lactic and propionic acid are the most common organic acids used 
in dairy products. 
 Acetic acid (pKa = 4.75) and acetates are the primary components of 
vinegar and are most effective against yeasts and bacteria.  Lactic acid (pKa = 
3.79) is produced during fermentation of LAB and acts as an antimicrobial, pH 
control agent and flavor enhancer (Davidson and Taylor, 2007).  Propionic acid 
(pKa = 4.87) is produced by propionibacterium.  The acid and its salts are 
primarily used against molds, but inhibit the growth of some yeast and bacteria 
as well.  
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2.3.2.4 Fermentates 
 In addition to organic acids and bacteriocins, fermentates are often used 
as food antimicrobials.  Fermentates are products of in situ controlled 
acidification by LAB; typically, the fermentation produces organic acids, low 
molecular weight proteins and other antimicrobial components, such as diacetyl 
(Montville and Chikindas, 2007).  The efficacy of fermentates is determined by 
the initial pH and buffering capacity of the product, characteristics of target 
microorganisms, type of fermentable carbohydrates, and the growth rates of the 
LAB and target pathogens at refrigerated and abuse temperatures.  Microgard, a 
cultured milk product produced through the fermentation of milk by 
Propionibacterium shermanii, is a GRAS food preservative; fermentation 
produces acetate, propionic acid and low molecular weight proteins.   
Microgard products are commercially available and claim to inhibit the 
growth of Gram-negative and Gram-positive organisms.  However, studies have 
shown that the efficacy of Microgard against Gram-positive organisms is 
dependent on the product.  In hamburger, Microgard products were able to 
reduce the counts of E. coli O157:H7, but could not inhibit the growth of L. 
monocytogenes (Dave et al., 2003).  Additionally, Microgard products could not 
inhibit the growth of L. innocua in liquid cheese whey (Staszewski and Jagus, 
2008).  Though Microgard products possess a bacteriocin, the main antimicrobial 
activity comes from the propionic acid, rendering its activity dependent upon the 
pH of the food matrix (Montville and Chikindas, 2007). 
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2.3.2.5 Glucose Oxidase 
 Glucose oxidase (GO) is a non-hydrolytic enzyme that has several 
applications in the beverage, pharmaceutical and food industries (Bankar et al., 
2009).  GO is used in the wine industry for its bactericidal activity against acetic 
and lactic acid bacteria; adding GO prevents the growth of spoilage bacteria and 
allows the use of fewer preservatives in wine.  It is also added to remove glucose 
from dried egg, removes oxygen from fruit juices and canned beverages, and 
improves the color, flavor and shelf life of foods (Bankar et al., 2009; 
Hatzinikolaou and Macris, 1995).  The most common sources for the 
fermentative production of GO are Aspergillus, Penicillium, and Saccharomyces 
species (Bankar et al., 2009).  GO uses molecular oxygen to catalyze the 
oxidation of β-D-glucose to gluconic acid and hydrogen peroxide (H2O2; Figure 
2.2).  
 
 
 
Figure 2.2 Representation of the glucose oxidase reaction.  
Source: Bankar, S. B., Bule, M. V., Singhal, R. S., & Ananthanarayan, L. (2009). Glucose oxidase - An 
overview. Biotechnology Advances, 27(4), 489-501. 
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GO has several antimicrobial applications involving the removal of residual 
glucose and oxygen in order to prolong the shelf life of foods.  Enzyme activity is 
dependent on the pH and optimum temperature.  The optimum pH of GO ranges 
from 5.0 to 7.0, while the temperature optimum ranges from 25°—60°C.   
Additionally, the H2O2 produced by the enzyme acts an effective bactericide.  The 
antimicrobial action of H2O2 is based on its strong oxidizing property and its ability 
to damage cellular components (Imlay and Linn, 1988; Ray and Bhunia, 2008).  
H2O2 has been used as an antimicrobial wash in fresh fruits and vegetables.  It 
was able to decrease the counts of Salmonella spp. in artificially inoculated 
whole and fresh cut pieces of cantaloupe and honeydew melons (Ukuku, 2004).  
Organism populations were reduced by 2.5 and 3 log CFU/g in whole cantaloupe 
and honeydew melons, respectively, after H2O2 washing treatments.  Additionally, 
H2O2 can be used in combination with lactoperoxidase, forming the antimicrobial 
lactoperoxidase system (discussed further below).  
 
2.3.2.6 Lactoperoxidase 
 Lactoperoxidase is a glycoprotein enzyme that is found in raw milk, 
colostrum and other biological secretions.  It belongs to the peroxidase family, a 
group of natural enzymes widely distributed in nature and found in plants and 
animals; lactoperoxidase catalyzes the peroxidation of thiocyanates to generate 
products that kill or inhibit the growth of many microorganisms (Kussendrager 
and van Hooijdonk, 2000).  It reacts with thiocyanate in the presence of hydrogen 
peroxide in order to form antimicrobial compounds; this reaction is termed the 
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lactoperoxidase system (LPS).  The thiocyanate ion oxidizes sulfhydryl groups to 
disulfides, sulfenylthiocyanates, or sulfenic acid.  The reaction of thiocyanate with 
NADH or interference with membrane proteins may cause leakage of the 
membrane or the loss of electrochemical potential, eventually leading to the 
inhibition of the transport of amino acids and sugars (Davidson and Taylor, 
2007).   
Hydrogen peroxide is necessary for the LPS to function as an 
antimicrobial.  It can be added to foods through the addition of hydrogen peroxide 
producing lactic acid bacteria (Ito et al, 2003) or by the enzymatic action of 
glucose oxidase.  The LPS is active against both Gram-negative and Gram-
positive bacteria, but different groups of bacteria have different levels of 
resistance to the LPS (Kussendrager and van Hooijdonk, 2000).  Antimicrobial 
reaction mechanisms of LPS are complex and their effectiveness depends on the 
intrinsic properties of the medium (pH, temperature, incubation time, cell density, 
etc.).  The LPS was bactericidal to Salmonella and was shown to inhibit the 
growth of E. coli O157:H7 and L. monoctygenes in milk when incubated at 4°C 
(Arques et al., 2008b; Zapico et al., 1998).  
 Commercially available SEA-i F75 contains lactoperoxidase and glucose 
oxidase.  Glucose oxidase functions to produce hydrogen peroxide, while the 
halide or thiocyanate must be present in the food matrix for the enzyme system 
to function properly.  
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2.3.2.7 Lysozyme 
 Lysozyme is an enzyme found in avian eggs, milk, insects, fish and some 
plant tissues.  Dried egg whites are the primary commercial source of lysozyme 
for foods (Davidson and Taylor, 2007).  The enzyme is relatively heat stable, with 
functionality at temperatures up to 100°C, but the enzyme’s optimum functionality 
is at temperatures between 55 and 60°C at pH values of 6.0 and 7.0. Lysozyme 
is most active against Gram-positive bacteria because the target of its 
antimicrobial action is the peptidoglycan of the cell wall; the enzyme works by 
catalyzing the hydrolysis of the α-1,4 glycosidic bonds between N-acetylmuramic 
acid and N-acetylglucosamine of the peptidoglycan in cell walls, causing cell 
degradation and lysis (Davidson and Taylor, 2007).  Ibrahim, Matsuzaki, & Aoki 
(2001) found that the bactericidal activity of lysozyme is independent of the 
enzyme’s catalytic activity.  Results suggest that there are two modes of 
catalytically independent bactericidal action:  1) an indirect bacteriolytic-
dependent mode and 2) a lysis-dependent mode that involves the regulation of 
cell wall-associated autolysins.  
Lysozyme is highly effective against L. monocytogenes strains.  Hughey & 
Johnson (1987) showed that four strains of L. monocytogenes isolates from food 
poisoning outbreaks were extremely susceptible to the activity of lysozyme.  Up 
to 80% of cells suspended in phosphate buffer, incubated at 4°C and treated with 
lysozyme (100 mg/liter) were lysed after 6 h of incubation.  Gram-negative cell 
susceptibility to lysozyme can be increased through the initial destabilization of 
the outer membrane by chemical (i.e. EDTA) or physical (i.e. freezing) means 
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(Branen and Davidson, 2004; Ray and Bhunia, 2008).  The food type, as well as 
processing and storage conditions, influences the antimicrobial activity of 
lysozyme.   
 
2.3.2.8 Lauric Arginate 
Lauric arginate (LAE) is a cationic preservative derived from lauric acid 
and arginine.  LAE also acts as a surfactant.  Surfactants possess antimicrobial 
activity due to their chemical properties; surfactants reduce the surface tension 
and the formation of ionic aggregates which leads to changes in conductivity and 
the solubility of solutions (Rodriguez et al., 2004).  In Gram-negative cells, LAE 
works by altering the cytoplasmic membrane and the external membrane while in 
Gram-positive cells, the surfactant works by altering the cell membrane and 
cytoplasm (Rodriguez et al., 2004).  Though the cells do not lyse, these 
alterations disrupt the membrane causing ion leakage and a loss of cell viability.   
Rodriguez, et al. (2004) examined the effects of LAE on S. Typhimurium 
and Staphylococcus aureus using transmission electron microscopy (TEM).  LAE 
initially induced severe damage of the S. Typhimurium bacterial membranes; an 
increase of damage was observed after 24 h.  The membrane of Staph. aureus 
was also severely damaged by the activity of the LAE, however, damage of the 
membrane progressed much more slowly.  LAE initially reduced the populations 
of L. monocytogenes by up to 2 log CFU/ml in milk and queso fresco cheese 
(QFC) when incubated at 4°C (Soni et al., 2010).  However, there was no 
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subsequent inhibitory effect by LAE; growth resume slowly during long-term 
storage of QFC at 4°C. 
 
2.4 Conclusion 
 Cheese consumption has been on the rise over the last decade.  Cheese 
is highly nutritious, providing both calcium and protein, but is also perceived as 
being high in sodium.  Unfortunately, excessive dietary sodium has several 
detrimental effects on cardiovascular health.  The negative health effects of 
excessive dietary sodium and consumers’ desire for products with reduced 
sodium have encouraged food manufacturers to reduce sodium in processed 
foods (Larson et al., 1993).  However, there are several challenges to overcome 
when reducing sodium.   
Studies have shown that pathogens have the ability to survive and/or grow 
in cheeses.  Decreasing sodium would diminish the major microbial hurdle in 
cheeses and could make cheeses more susceptible to pathogenic growth if 
contaminated.  In order to remove the sodium in cheese and avoid unfavorable 
changes to the product, salt replacers and antimicrobials may be a necessary 
addition to ensure product safety and consumer acceptability.  This study 
examines the antimicrobial efficacy of several antimicrobials and salt substitutes 
in agar and cheese systems with the intent of finding a suitable antimicrobial for 
use in low sodium low-moisture part-skim mozzarella cheese.   
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3.0 Antimicrobial Efficacy Screening in TSA 
 
3.1 Objectives 
 To determine the antimicrobial efficacy of commercially available 
antimicrobials and sodium replacement agents in tryptic soy agar (TSA). 
 
3.2 Hypothesis 
 Antimicrobials and sodium replacement agents will inhibit the growth of 
Salmonella, Listeria monocytogenes and E. coli O157:H7. 
 
3.3 Materials and Methods 
 
3.3.1 Bacterial Strains  
  Five strains of each E. coli O157:H7, Listeria monocytogenes and 
Salmonella were used in the study.  E. coli O157:H7 strains NFPA 4212, NFPA 
4213, NFPA 4216, NFPA 4217, and NFPA 4219 were obtained from the culture 
collection of the National Food Laboratory (Livermore, CA).  Two of the Listeria 
monocytogenes strains, NFPA 6301 and NFPA 6306, were obtained from the 
culture collection of the National Food Laboratory (Livermore, CA) while the other 
three strains, NRRL B-33000, NRRL B-33096, and NRRL B-33113 were received 
from the National Center for Agricultural Utilization Research (Peoria, IL).  
Salmonella enterica strains, Salmonella Javiana FSL S5-406, Salmonella 
Enteriditis FSL S5-415, Salmonella Heidelburg FSL S5-448, Salmonella 
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Oranienburg FSL S5-642, and Salmonella Typhimurium FSL W1-030, were 
obtained from the International Life Sciences Institute, North America (Cornell 
University, Ithaca, NY).  
 All strains were stored in cryogenic vials (Fisher Scientific, Hanover Park, 
IL) at -70°C for long-term preservation.  Prior to use, cultures were streaked on 
selective media and incubated at 35°C for 24 h.  Salmonella strains were 
streaked on Xylose Lysine Deoxycholate Agar (XLD, Neogen, Lansing, MI), while 
Modified Oxford Agar (MOX, Difco, Sparks, MD) was used for Listeria 
monocytogenes and MacConkey Agar with Sorbitol (SMAC, Neogen, Lansing, 
MI) was used for E. coli O157:H7.  Isolated colonies were used for inoculum 
preparation.  
 
3.3.2 Preparation of Inocula 
 Each strain was individually transferred into 10 ml of Tryptic Soy Broth 
(TSB, Neogen, Lansing, MI) and grown at 35°C for 18 h.  After incubation, equal 
volumes of each strain were pooled within a species to form a cocktail.  Each 
cocktail was centrifuged (1,800 g x 15 min), washed twice with 0.1% peptone 
water and resuspended in 0.1% peptone water.  Direct microscope count (DMC) 
was done with a Petroff-Hausser Counting Chamber (Hausser Scientific, 
Horsham, PA) to determine the initial stock concentration.  Cocktails were diluted 
to the target concentration using 0.1% peptone water.  Initial counts were 
confirmed by plating on Tryptic Soy Agar (TSA, Neogen, Lansing, MI) and 
incubating at 35°C for 24h.  
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3.3.3 Antimicrobials and Sodium Replacement Agents 
  Eight antimicrobials received from several suppliers were used in the 
study, and consisted of  MicroGard 100, MicroGard 430, Nisaplin, NovaGard 
CB1, Protect-M, PuraQ Verdad RV 75, SEA-i F75 and VMY1P (Table 3.1).  Six 
sodium replacement agents received from several suppliers were also used in 
the study, and included potassium chloride, Puracal PP/USP, PuraQ Verdad 
NV10, Purasal Hi Pure P Plus, SaltWise 0029 and SaltWise 1029 (Table 3.2).  
Antimicrobials and sodium replacement agents were stored per manufacturer’s 
recommendation until used in the study.   
 
3.3.4 Antimicrobial Efficacy Determination 
  Antimicrobial efficacy experiments were performed in duplicate.  The 
efficacy of the antimicrobials was determined using an agar dilution method 
(Oussalah et al., 2007b).  TSA was adjusted to pH 5.8, using 1N HCl, to mimic 
typical pH conditions of mozzarella cheese.  After pH adjustment, antimicrobials 
or sodium replacement agents were added to agar at various concentrations 
(Tables 3.1 and 3.2).  Concentrations used for each antimicrobial and sodium 
replacement agent were determined using manufacturer recommendations.  The 
supplemented agars were poured into sterile petri plates and allowed to solidify.  
Salmonella, L. monocytogenes or E. coli O157:H7 was spread plated onto 
solidified TSA at a target concentration of 101, 102 and 104 CFU/ml.  
Uninoculated TSA plates served as negative controls while inoculated plates, 
without antimicrobial added, served as positive controls.  Uninoculated 
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supplemented agar plates were also tested for pH.  All test and control plates 
were incubated at 35°C for 48 h.  Plates were observed after 24 h and 48 h for 
presence or absence of growth.  For all plates, absence of growth indicated the 
antimicrobial had an inhibitory effect. 
 
Table 3.1 Description and concentrations of antimicrobials used to determine antimicrobial efficacy 
in tryptic soy agar (TSA) screening. 
Antimicrobial Manufacturer Product Description Concentrations Used (%) 
       
MicroGard 100 Danisco 
Cultured Grade A Nonfat Dry Milk 
Powder; Diacetyl; Organic Acids 
0.5 0.75 1.0 2.0 
       
MicroGard 430 Danisco 
Cultured Grade A Nonfat Dry Milk 
Powder; Maltodextrin; Diacetyl; Organic 
Acids 
0.5 0.75 1.0 2.0 
       
Nisaplin Danisco Nisin; NaCl 0.03 0.05 0.10  
       
NovaGard 
CB1 
Danisco 
Maltodextrin; Cultured Dextrose; Sodium 
Diacetate; NaCl; Lysozyme; Nisin 
0.5 0.75 1.0 2.0 
       
Protect-M Purac Lauric Arginate 0.10 0.15 0.20 0.40 
       
PuraQ Verdad 
RV75 
Purac 
Cultured Sugar; Organic Acids; Residual 
Sugars 
0.1 0.2 0.4  
       
SEA-i F75 Bienca 
Glucose; Glucose Oxidase; Whey; 
Lactoperoxidase; Lactose; Casein 
0.25 0.50   
       
VMY1P Purac Cultured Whey 0.5 0.75 1.0  
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Table 3.2 Description and concentrations of sodium replacement agents used to determine 
antimicrobial efficacy in tryptic soy agar (TSA). 
 
 
3.4 Results 
 
3.4.1 Efficacy of antimicrobials against Salmonella, E. coli O157:H7 and L. 
monocytogenes in TSA 
 MicroGard 100, Nisaplin and VMY1P did not inhibit the growth of any of 
the organisms tested at any of the inoculum levels tested (Tables 3.3, 3.5 and 
3.10).  Growth of Salmonella and E. coli O157:H7 was detected after 24 h of 
incubation in TSA supplemented with MicroGard 430 (Table 3.4).  However, at a 
concentration of 2.0%, MicroGard 430 delayed the growth of L. monocytogenes 
at inoculum levels of 101 and 102 CFU/ml.   NovaGard CB1 at concentrations 
Sodium Replacement 
Agents 
Manufacturer Product Description 
Concentrations Used 
(%) 
      
Potassium Chloride Cargill Potassium chloride 1.0 2.0  
      
Puracal PP/USP Purac Calcium lactate 0.02 0.04  
      
Puracal Hi Pure P 
Plus 
Purac Potassium lactate 0.02 0.04 
 
      
PuraQ Verdad NV10 Purac Cultured corn sugar 0.02 0.04  
      
SaltWise 0029 Cargill 
Potassium chloride; trehalose; 
autolyzed yeast extract; silicon 
dioxide 
0.5 1.0 2.0 
      
SaltWise 1029 Cargill 
Potassium chloride; trehalose; 
autolyzed yeast extract; silicon 
dioxide 
0.5 1.0 2.0 
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less than 2.0% could not inhibit the growth of Salmonella, E. coli O157:H7 or L. 
monocytognes (Table 3.6).  At a concentration of 2.0%, NovaGard CB1 delayed 
the growth of all three organisms at all inoculum levels tested.  Protect-M and 
SEA-i F75 completely inhibited all three organisms tested at all inoculum levels 
and all antimicrobial concentrations (Tables 3.7 and 3.9).  PuraQ Verdad RV75 at 
a concentration of 0.1% could not inhibit the growth of E. coli O157:H7, 
Salmonella, or L. monocytogenes in TSA (Table 3.8).  At a concentration of 
0.2%, growth of E. coli O157:H7 and the highest inoculum level of Salmonella 
were not inhibited, while the growth of the lowest inoculum levels of Salmonella 
and all levels L. monocytogenes were partially inhibited by PuraQ Verdad RV75 
in TSA. 
 
Table 3.3 Growth of Salmonella and E. coli O157:H7 on TSA (pH 5.8) supplemented with 
MicroGard 1001 and incubated at 35°C.  
Antimicrobial 
Concentration 
Target Organism 
Concentration (CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 
    
0.5% 
(pH 5.92) 
 
5.0 X 101 24 h 24 h 
5.0 X 102 24 h 24 h 
5.0 X 104 24 h 24 h 
    
0.75% 
(pH 5.81) 
5.0 X 101 24 h 24 h 
5.0 X 102 24 h 24 h 
5.0 X 104 24 h 24 h 
    
1.0% 
(pH 5.78) 
5.0 X 101 24 h 24 h 
5.0 X 102 24 h 24 h 
5.0 X 104 24 h 24 h 
    
2.0% 
(pH 5.64) 
5.0 X 101 24 h 24 h 
5.0 X 102 24 h 24 h 
5.0 X 104 24 h 24 h 
    
1
MicroGard 100 was only challenged against Salmonella and E. coli O157:H7 as manufacturer 
recommended use against Gram-negative organisms.  
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Table 3.4 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with MicroGard 430 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.50% 
(pH 6.05) 
 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.75% 
(pH 5.82) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
1.0% 
(pH 5.45) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
2.0% 
(pH 5.02) 
5.0 X 101 24 h 24 h 48 h 
5.0 X 102 24 h 24 h 48 h 
5.0 X 104 24 h 24 h 24 h 
     
 
 
Table 3.5 Growth of Listeria monocytogenes on TSA (pH 5.8) supplemented with Nisaplin and 
incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism Concentration (CFU/ml) Time Until Observed Organism Growth 
   
0.03% 
(pH 5.84) 
5.0 X 101 24 h 
5.0 X 102 24 h 
5.0 X 104 24 h 
   
0.05% 
(pH 5.82) 
5.0 X 101 24 h 
5.0 X 102 24 h 
5.0 X 104 24 h 
   
0.10% 
(pH 5.79) 
5.0 X 101 24 h 
5.0 X 102 24 h 
5.0 X 104 24 h 
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Table 3.6 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with NovaGard CB1 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.50% 
(pH 5.97) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.75% 
(pH 5.84) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
1.0% 
(pH 5.76) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
2.0% 
(pH 5.36) 
5.0 X 101 48 h 48 h 48 h 
5.0 X 102 48 h 48 h 48 h 
5.0 X 104 48 h 48 h 48 h 
     
 
Table 3.7 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with Protect-M and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
0.10% 
(pH 5.81) 
5.0 X 101 NG1 NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
0.15% 
(pH 5.78) 
5.0 X 101 NG NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
0.20% 
(pH 5.71) 
5.0 X 101 NG NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
0.40% 
(pH 5.71) 
5.0 X 101 NG NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
 45 
 
Table 3.8 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with PuraQ Verdad RV75 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.1% 
(pH 5.83) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.2% 
(pH 5.77) 
5.0 X 101 48 h 24 h 48 h 
5.0 X 102 24 h 24 h 48 h 
5.0 X 104 24 h 24 h 48 h 
     
0.4% 
(pH 5.60) 
5.0 X 101 NG1 NG NG 
5.0 X 102 48 h NG NG 
5.0 X 104 48 h 48 h NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
 
 
Table 3.9 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with SEA-i F75 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.25% 
(pH 5.82) 
5.0 X 101 NG1 NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
0.50% 
(pH 5.44) 
5.0 X 101 NG NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 3.10 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with VMY1P and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.50% 
(pH 5.40) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.75% 
(pH 5.38) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
1.0% 
(pH 5.27) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
 
 
3.4.2 Antimicrobial activity of sodium replacement agents in TSA 
 There was no antimicrobial activity detected in any of the sodium 
replacement agents tested (Tables 3.11-3.16).  Growth of Salmonella, E. coli 
O157:H7 and L. monocytogenes was detected after 24 h of incubation in all test 
conditions.   
Table 3.11 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with KCl and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
1.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
2.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
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Table 3.12 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with Puracal PP/USP and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.02% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.04% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
 
Table 3.13 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with Purasal Hi Pure P Plus and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.02% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.04% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
 
Table 3.14 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with PuraQ Verdad NV10 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.02% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.04% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
 
 48 
 
Table 3.15 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA (pH 5.8) 
supplemented with SaltWise 0029 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.5% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
1.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
2.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
 
 
Table 3.16 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on TSA supplemented 
with SaltWise 1029 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.5% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
1.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
2.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
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3.5 Discussion 
 Antimicrobials were screened for efficacy in order to reduce the number of 
antimicrobials used in the final cheese study.  The eight antimicrobials screened 
consisted of four fermentates (MicroGard 100, MicroGard 430, PuraQ Verdad 
RV75 and VMY1P), a bacteriocin (Nisaplin), a lysozyme-containing blend 
(NovaGard CB1), lauric arginate (Protect-M) and a lactoperoxidase system 
(SEA-i F75).  Fermentates are products of the in situ lactic acid bacteria (LAB) 
controlled acidification  (Montville and Chikindas, 2007).  This controlled 
acidification generates fermentation by products, such as organic acids, diacetyl 
and bacteriocin-like products, that are antimicrobial alone and in combination 
with each other.   Fermentates used in this study included MicroGard 100, 
MicroGard 430, PuraQ Verdad RV75 and VMY1P.   
 One of the major antimicrobial components of fermentates is organic 
acids.  Though the antimicrobial mechanism of organic acids is not fully 
understood, the possible bacterial targets include the cell wall, cytoplasmic 
membrane and metabolic functions within the cytoplasm (Ricke, 2003).  It is 
believed that the undissociated forms of organic acids diffuse through the lipid 
membrane of the bacterial cell and, once inside the cytoplasm, dissociate into 
anions and protons.  The increase in protons acidifies the cytoplasm and the 
bacterium must use energy, in the form of ATP, to pump excess protons out of 
the cell.  The amount of time it takes to increase the pH to a point where growth 
may resume, or lag time, is dependent on the inhibitor concentration and the 
extracellular pH (Davidson and Taylor, 2007).  Antimicrobial effectiveness of 
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organic acids is related to pH and the acid dissociation constant, or pKa.  
Generally, the undissociated form of the acid is responsible for the antimicrobial 
effectiveness of organic acids; organic acids are more effective when the majority 
of the acid is in the undissociated form or when the pH < pKa.  
MicroGard 100 and MicroGard 430 provided little to no inhibition of the 
organisms tested in TSA.  MicroGard products are produced through the 
fermentation of grade A skim milk by Propionibacterium shermanii.  Antimicrobial 
activity of MicroGard products is derived from the bacteriocin-like products, 
including diacetyl as well as lactic, acetic and propionic acids, produced during 
fermentation (Stasweski and Jagus, 2008).  Lactic, acetic and propionic acids 
have pKa values of 3.79, 4.75 and 4.87, respectively.  The pH of TSA in this 
study, after adjustment and the addition of Microgard products, was 5.02 or 
greater.  Since the pH is greater than each of the respective pKa values the 
majority of the acid would be in the dissociated form and the antimicrobial 
efficacy of the organic acid would be reduced.  
 In addition to the organic acids, MicroGard products contain diacetyl 
which has been shown to possess broad antimicrobial activity when utilized at 
concentrations ranging between 200 and 1000 ppm (Lanciotti et al., 2003).  
Diacetyl inhibited the growth of E. coli, Salmonella, S. aureus, and 
L.monocytogenes, with Gram-positive organisms showing more resistance (Kang 
and Fung, 1999; Lanciotti et al., 2003).  In this study, diacetyl, despite being 
combined with other components of MicroGard products, proved to be ineffective 
at inhibiting the organisms tested in TSA, an ideal medium for bacterial growth.  
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Though the concentration of diacetyl in the MicroGard products was not 
determined in this study, diacetyl, at a concentration of 344 ppm, previously 
lacked effectiveness against Gram-negative and Gram-positive organisms in BHI 
broth, another ideal medium (Jay, 1982).  Preliminary studies showed the lack of 
effectiveness in BHI was most likely due to the nutrient composition of the 
medium and the relatively high incubation temperature; diacetyl is more effective 
at 10° and 20°C than at 37°C. The combination of the elevated temperature, 
higher pH and the nutrient-rich medium created an environment that was 
extremely ideal for the growth of microorganisms, reducing the efficacy of the 
MicroGard products.  
The other two fermentates tested were PuraQ Verdad RV75 and VMY1P.  
PuraQ Verdad RV75 provided partial inhibition while VMY1P could not inhibit the 
growth of the three organisms tested in TSA.  Exact components and active 
ingredients of PuraQ Verdad RV75 and VMY1P are not known.  However, as 
products are typically cultured by Lactobacillus species, it is likely they contain 
mainly lactic acid and trace amounts of acetate or propionate.  As previously 
stated, antimicrobial activity of organic acids relies heavily on the pH of the 
environment.  TSA was adjusted to a pH of 5.8 prior to the addition of the 
antimicrobials to simulate the pH of mozzarella cheese.  After the addition of the 
fermentates, the lowest pH values observed for PuraQ Verdad RV75 and VMY1P 
were 5.60 and 5.27, respectively.  These pH values are much higher than the 
pKa of the organic acids.  The concentrations of PuraQ Verdad RV75 and 
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VMY1P used in this study were not able to provide antimicrobial activity at such a 
high pH value and under such favorable conditions for microbial growth.  
Nisaplin, at the concentrations used in this study, was unable to prevent 
the growth of L. monocytogenes in TSA.  The active component in Nisaplin is 
nisin, a bacteriocin produced by Lactococcus lactis.  Bacteriocins attach to the 
cell wall and act by creating pores in the cellular membrane, which causes 
cytoplasmic leakage, eventually leading to cell lysis (Dave et al., 2003).  The 
antimicrobial activity of nisin is dependent upon the incubation temperature and 
pH of the product; in general, nisin is most effective against Gram-positive 
organisms and at lower incubation temperatures and in acidic environments 
(Montville and Chikindas, 2007).  After pH adjustment and the addition of 
Nisaplin, the pH of TSA remained close to 5.8 at every concentration tested.  
Growth of L. monoytogenes was permitted in tryptic soy broth (TSB) after 
supplementation with Nisaplin at pH values of less than 5.60 (Boziaris and 
Nychas, 2006).  The efficacy of nisin is highly dependent upon the presence of 
other microbial hurdles, such as low pH and low incubation temperatures.  The 
absence of other microbial hurdles, low incubation temperature or acidic 
environment, Nisaplin was ineffective at preventive microbial growth.   
NovaGard CB1 delayed the growth of test pathogens when used at a 
concentration of 2.0% in TSA.  NovaGard CB1 is a blend of lysozyme, nisin and 
other organic acids which allows it to attack several different cells target areas 
simultaneously.  Lysozyme,  the primary antimicrobial compound in egg 
albumen, works by attacking the peptidoglycan of the cell wall, causing 
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degradation and lysis (Davidson and Taylor, 2007).  Lysozyme is typically more 
effective at lower temperatures where cell growth is slowed (Hughey and 
Johnson, 1987).  The elevated incubation temperature used in this study 
promoted the rapid growth of the microorganisms tested; it is likely that the cell 
wall synthesis in the rapidly growing cultures exceeded the rate of cell wall 
degradation by the lysozyme.  Lysozyme is also most active against Gram-
positive bacteria because of the accessibility to the peptidoglycan of the cell wall.  
However, in this study, a delay in the growth of Gram-negative organisms was 
also observed.  Other active components in NovaGard CB1 potentially 
contributed to this delay in growth.  
Protect-M, a commercial source of lauric arginate (LAE), was highly 
effective at inhibiting all three organisms in TSA.  In Gram-negative cells, LAE 
works by altering the cytoplasmic membrane and the external membrane while in 
Gram-positive cells, the surfactant works by altering the cell membrane and 
cytoplasm (Rodriguez et al., 2004).  Though the cells do not lyse, these 
alterations disrupt the membrane causing ion leakage and a loss of cell viability.  
Efficacy of LAE is determined by the food matrix; as a cationic surfactant, it may 
interact with anionic components of the food matrix through electrostatic 
interactions resulting in either an enhancement or reduction of its activity (Asker 
et al., 2009). Protect-M provided inhibition against Gram-negative and Gram-
positive cells in TSA; it stands to reason that the lauric arginate interacted with 
anionic components in the agar, most likely chloride, which resulted in an 
enhancement of its antimicrobial activity. 
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SEA-i F75, a lactoperoxidase-based system, inhibited the growth of the 
three organisms tested.  Mechanisms of antimicrobial activity of the 
lactoperoxidase system include the deactivation of cellular enzymes, interference 
with membrane proteins and the inhibition of the transport of amino acids and 
sugars.  The activity of lactoperoxidase is dependent upon the presence of 
hydrogen peroxide (H2O2) and either thiocyanate or a halide.  Because 
lactoperoxidase needs H2O2, SEA-i F75 contains glucose oxidase, which utilizes 
glucose and oxygen to produce H2O2.  Lactoperoxidase is highly inihibitory to 
Gram-negative pathogens and has exhibited antimicrobial activity against Gram-
positive organisms as well (Arques et al., 2008a; Arques et al., 2008b; Davidson 
and Taylor, 2007). 
Our results showed that SEA-i F75 was highly effective at inhibiting the 
growth of Gram-negative and Gram-positive organisms.  Since thiocyanate was 
not added to the agar, we presume that TSA supported the action of the 
lactoperoxidase in SEA-i F75 by contributing chloride, the necessary halide, in 
addition to the H2O2 produced by the glucose oxidase, for antimicrobial activity.  
The six sodium replacement agents tested consisted of two lactates, a 
fermentate and three containing KCl.  Sodium replacement agents were tested 
for antimicrobial activity to determine if they could be used solely (without the 
addition of an antimicrobial) or if they could potentially increase the efficacy of an 
antimicrobial in the food matrix.  No antimicrobial activity was observed when 
sodium replacement agents were tested in TSA.  Though the main function of 
these products is to enhance the flavor of low sodium products, KCl has also 
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been shown to have some antimicrobial activity.  Equal molar concentrations of 
NaCl and KCl have shown similar antimicrobial effects, in terms of lag time, 
growth or death rate, against L. monocytogenes (Boziaris et al., 2007).  KCl is 
able to inhibit the growth of microorganisms through a reduction in water activity, 
similar to NaCl.  However, water activity between agars supplemented with each 
of the sodium replacement agents did not vary significantly and KCl did not 
display any inhibitory activity in this study (data not show).  The TSA matrix is 
highly favorable for the growth of microorganisms; sodium replacement agents, 
at the concentrations tested, did not provide any inhibition of the microorganisms 
in TSA.  
 
3.6 Conclusion 
 Four antimicrobials, NovaGard CB1, Protect-M, PuraQ Verdad RV75 and 
SEA-i F75 showed the most inhibition of E. coli O157:H7, Salmonella and L. 
monocytogenes growth in TSA.  The composition of the food matrix can affect 
the growth of the microorganisms as well as the efficacy of antimicrobials. 
Because of this, all antimicrobials were challenged in milk agar to determine if 
the change in the matrix composition would affect the antimicrobial efficacy. 
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4.0 Antimicrobial Efficacy Screening in Milk Agar 
 
4.1 Objectives 
 To determine the antimicrobial efficacy of commercially available 
antimicrobials and sodium replacement agents in milk agar. 
 
4.2 Hypothesis 
 Efficacy of antimicrobials and sodium replacement agents will be 
increased in milk agar.  
 
4.3 Materials and Methods 
  
4.3.1 Bacterial Strains 
  Five strains of each E. coli O157:H7, Listeria monocytogenes and 
Salmonella were used in the study.  E. coli O157:H7 strains NFPA 4212, NFPA 
4213, NFPA 4216, NFPA 4217, and NFPA 4219 were obtained from the culture 
collection of the National Food Laboratory (Livermore, CA).  Two of the Listeria 
monocytogenes strains, NFPA 6301 and NFPA 6306, were obtained from the 
culture collection of the National Food Laboratory (Livermore, CA) while the other 
three strains, NRRL B-33000, NRRL B-33096, and NRRL B-33113 were received 
from the National Center for Agricultural Utilization Research (Peoria, IL).  
Salmonella enterica strains, Salmonella Javiana FSL S5-406, Salmonella 
Enteriditis FSL S5-415, Salmonella Heidelburg FSL S5-448, Salmonella 
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Oranienburg FSL S5-642, and Salmonella Typhimurium FSL W1-030, were 
obtained from the International Life Sciences Institute, North America (Cornell 
University, Ithaca, NY).  
 All strains were stored in cryogenic vials (Fisher Scientific, Hanover Park, 
IL) at -70°C for long-term preservation.  Prior to use, cultures were streaked on 
selective media and incubated at 35°C for 24 h.  Salmonella strains were 
streaked on Xylose Lysine Deoxycholate Agar (XLD, Neogen, Lansing, MI), while 
Modified Oxford Agar (MOX, Difco, Sparks, MD) was used for Listeria 
monocytogenes and MacConkey Agar with Sorbitol (SMAC, Neogen, Lansing, 
MI) was used for E. coli O157:H7.  Isolated colonies were used for inoculum 
preparation.  
 
4.3.2 Preparation of Inocula 
  Each strain was individually transferred into 10 ml of Tryptic Soy Broth 
(TSB, Neogen, Lansing, MI) and grown at 35°C for 18 h.  After incubation, equal 
volumes of each strain were pooled within a species to form a cocktail.  Each 
cocktail was centrifuged (1,800 g x 15 min), washed twice with 0.1% peptone 
water and resuspended in 0.1% peptone water.  Direct microscope count (DMC) 
was done with a Petroff-Hausser Counting Chamber (Hausser Scientific, 
Horsham, PA) to determine the initial stock concentration.  Cocktails were diluted 
to the target concentration using 0.1% peptone water.  Initial counts were 
confirmed by plating on Tryptic Soy Agar (TSA, Neogen, Lansing, MI) and 
incubating at 35°C for 24h.  
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4.3.3 Antimicrobials and Sodium Replacement Agents 
  Eight antimicrobials received from several suppliers were used in the 
study (Table 4.1).  They consisted of MicroGard 100, MicroGard 430, Nisaplin, 
NovaGard CB1, Protect-M, PuraQ Verdad RV 75, SEA-i F75 and VMY1P.  Six 
sodium replacement agents received from several suppliers were also used in 
the study (Table 4.2).  These included potassium chloride, Puracal PP/USP, 
PuraQ Verdad NV10, Purasal Hi Pure P Plus, SaltWise 0029 and SaltWise 1029.  
Antimicrobials and sodium replacement agents were stored per manufacturer’s 
recommendation until used in the study.   
 
4.3.4 Antimicrobial Efficacy Determination  
  The efficacy of the antimicrobials was determined using an agar dilution 
method (Oussalah et al., 2007b).  Milk agar was prepared by dissolving nonfat 
dry milk (8 g/L) and agar (15 g/L) in deionized water.  Agar was autoclaved at 
121°C for 15 minutes then tempered prior to use.  Antimicrobials and sodium 
replacement agents were added to tempered milk agar at various concentrations 
(Tables 4.1 and 4.2).  Concentrations used for each antimicrobial and sodium 
replacement agent were determined using manufacturer recommendations and 
preliminary results in tryptic soy agar (TSA).  The supplemented agars were 
poured into sterile petri plates and allowed to solidify.  Salmonella, L. 
monocytogenes or E. coli O157:H7 was spread plated onto solidified milk agar at 
a target concentration of 101, 102 and 104 CFU/ml.  Uninoculated milk agar plates 
served as negative controls while inoculated plates, without antimicrobial added, 
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served as positive controls.  Uninoculated supplemented agar plates were also 
tested for pH.  All test and control plates were incubated at 35°C for 48 h.  Plates 
were observed after 24 h and 48 h for presence or absence of growth.  For all 
plates, absence of growth indicated the antimicrobial had an inhibitory effect.  
Table 4.1 Description and concentrations of antimicrobials used to determine antimicrobial efficacy 
in milk agar screening. 
Antimicrobial Manufacturer Product Description 
Concentrations Used 
(%) 
     
MicroGard 100 Danisco 
Cultured Grade A Nonfat Dry Milk Powder; 
Propionic Acid; Acetate 
0.5 1.0 
     
MicroGard 430 Danisco 
Cultured Grade A Nonfat Dry Milk Powder; 
Maltodextrin; Propionic Acid; Acetate 
0.5 1.0 
     
Nisaplin Danisco Nisin; NaCl 0.03 0.10 
     
NovaGard 
CB1 
Danisco 
Maltodextrin; Cultured Dextrose; Sodium 
Diacetate; NaCl; Lysozyme; Nisin 
1.0 2.0 
     
Protect-M Purac Lauric Arginate 0.10 0.20 
     
PuraQ Verdad 
RV75 
Purac 
Cultured Sugar; Organic Acids; Residual 
Sugars 
0.2 0.4 
     
SEA-i F75 Bienca 
Glucose; Glucose Oxidase; Whey; 
Lactoperoxidase; Lactose; Casein 
0.25 0.50 
     
VMY1P Purac Cultured Whey 0.5 1.0 
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Table 4.2 Description and concentrations of sodium replacement agents used to determine 
antimicrobial efficacy in milk agar. 
 
 
4.4 Results 
 
4.4.1 Efficacy of Antimicrobials against Salmonella, E. coli O157:H7 and L. 
monocytogenes in Milk Agar   
At a MicroGard 100 concentration of 0.5%, Salmonella and E. coli 
O157:H7 grew on supplemented milk agar at all inoculum levels after 24 h (Table 
4.3).  Increasing the concentration of MicroGard 100 to 1.0% delayed the growth 
of E. coli O157:H7 at the lowest inoculum concentration and Salmonella at all 
concentrations.  At a MicroGard 430 concentration of 0.5%, L. monocytogenes, 
Salmonella and E. coli O157:H7 grew on the supplemented milk agar at all 
Sodium Replacement 
Agents 
Manufacturer Product Description 
Concentrations Used 
(%) 
     
Potassium Chloride Cargill Potassium chloride 1.0 2.0 
     
Puracal PP/USP Purac Calcium lactate 0.02 0.04 
     
Puracal Hi Pure P 
Plus 
Purac Potassium lactate 0.02 0.04 
     
PuraQ Verdad NV10 Purac Cultured corn sugar 0.02 0.04 
     
SaltWise 0029 Cargill 
Potassium chloride; trehalose; 
autolyzed yeast extract; silicon 
dioxide 
1.0 2.0 
     
SaltWise 1029 Cargill 
Potassium chloride; trehalose; 
autolyzed yeast extract; silicon 
dioxide 
1.0 2.0 
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inoculum levels after 24 h (Table 4.4).  An increase in concentration to 1.0% did 
not affect L. monocytogenes; however, the growth of E. coli O157:H7 at the 
lowest inoculum level and Salmonella at all inoculum levels was delayed.  
Growth of L. monocytogenes was observed in milk agar supplemented with 
Nisaplin, at the highest and lowest inoculum level after 24 h and 48 h, 
respectively (Table 4.5).  NovaGard CB1 completely inhibited the growth of 
Salmonella, E. coli O157:H7 and L. monocytogenes in milk agar at all 
antimicrobial concentrations and inoculum levels tested (Table 4.6).  Protect-M 
was highly effective at inhibiting the growth of L. monocytogenes and E. coli 
O157:H7 in milk agar (Table 4.7).  All test conditions yielded no growth of either 
organism after 48 h.  However, growth of Salmonella was observed at all 
inoculum levels with an antimicrobial concentration of 0.1% after 48h.  A 
concentration of 0.2% was needed to inhibit the growth of Salmonella.  PuraQ 
Verdad RV75 and SEA-i F75 completely inhibited the growth of Salmonella, E. 
coli O157:H7 and L. monocytogenes in milk agar at all antimicrobial 
concentrations and inoculum levels tested (Tables 4.8 and 4.9).  Growth of 
Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar supplemented 
with VMY1P at a concentration of 0.5% was detected after 48 h of incubation.  
Increasing the concentration to 1.0% inhibited the growth of all organisms tested 
at all inoculum levels.  
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Table 4.3 Growth of Salmonella and E. coli O157:H7 on milk agar supplemented with MicroGard 100 and 
incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration (CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 
    
0.5% 
(pH 6.72) 
5.0 X 101 24 h 24 h 
5.0 X 102 24 h 24 h 
5.0 X 104 24 h 24 h 
    
1.0% 
(pH 6.71) 
5.0 X 101 48 h 48 h 
5.0 X 102 48 h 24 h 
5.0 X 104 48 h 24 h 
    
 
 
Table 4.4 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with MicroGard 430 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.50% 
(pH 5.93) 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
1.0% 
(pH 5.61) 
5.0 X 101 48 h 48 h 24 h 
5.0 X 102 48 h 24 h 24 h 
5.0 X 104 48 h 24 h 24 h 
     
 
 
Table 4.5 Growth of Listeria monocytogenes on milk agar supplemented with Nisaplin and 
incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
0.03% 
(pH 6.74) 
5.0 X 101 48 h 
5.0 X 102 48 h 
5.0 X 104 24 h 
   
0.10% 
(pH 6.66) 
5.0 X 101 48 h 
5.0 X 102 48 h 
5.0 X 104 24 h 
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Table 4.6 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with NovaGard CB1 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
1.0% 
(pH 5.49) 
5.0 X 101 NG1 NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
2.0% 
(pH 5.27) 
5.0 X 101 NG NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
 
Table 4.7 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with Protect-M and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.10% 
(pH 6.41) 
5.0 X 101 48 h NG NG 
5.0 X 102 48 h NG NG 
5.0 X 104 48 h NG NG 
     
0.20% 
(6.42) 
5.0 X 101 NG1 NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
 
Table 4.8 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with PuraQ Verdad RV75 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
0.2% 
(pH 4.78) 
5.0 X 101 NG1 NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
0.4% 
(pH 4.70) 
5.0 X 101 NG NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 4.9 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with SEA-i F75 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.25% 
(pH 5.39) 
5.0 X 101 NG1 NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
0.50% 
(pH 4.97) 
5.0 X 101 NG NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
 
 
Table 4.10 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with VMY1P and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.50% 
(pH 5.67) 
5.0 X 101 24 h 48 h 48 h 
5.0 X 102 24 h 24 h 48 h 
5.0 X 104 24 h 24 h 24 h 
     
1.0% 
(pH 5.38) 
5.0 X 101 NG1 NG NG 
5.0 X 102 NG NG NG 
5.0 X 104 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
 
 
4.4.2 Antimicrobial Activity of Sodium Replacement Agents in Milk Agar 
 There was no antimicrobial activity detected in any of the sodium 
replacement agents tested (Tables 4.11-4.16).  Growth of Salmonella, E. coli 
O157:H7 and L. monocytogenes was detected after 24 h of incubation in all test 
conditions. 
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Table 4.11 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with KCl and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
1.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
2.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
 
Table 4.12 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with Puracal PP/USP and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.02% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.04% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
 
Table 4.13 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with Purasal Hi Pure P Plus and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.02% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
0.04% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
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Table 4.14 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with PuraQ Verdad NV10 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
0.02% 
5.0 X 101 24 h 24 h 48 h 
5.0 X 102 24 h 24 h 48 h 
5.0 X 104 24 h 24 h 48 h 
     
0.04% 
5.0 X 101 24 h 24 h 48 h 
5.0 X 102 24 h 24 h 48 h 
5.0 X 104 24 h 24 h 48 h 
     
 
Table 4.15 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with SaltWise 0029 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
1.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
2.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
 
Table 4.16 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes on milk agar 
supplemented with SaltWise 1029 and incubated at 35°C. 
Antimicrobial 
Concentration 
Target Organism 
Concentration 
(CFU/ml) 
Time Until Observed Organism Growth 
Salmonella E. coli O157:H7 L. monocytogenes 
     
1.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
     
2.0% 
5.0 X 101 24 h 24 h 24 h 
5.0 X 102 24 h 24 h 24 h 
5.0 X 104 24 h 24 h 24 h 
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4.5 Discussion 
MicroGard 100 and MicroGard 430 provided partial to no inhibition of the 
organisms tested in milk agar.  Specific antimicrobial mechanisms were 
discussed in Chapter 3.  Despite changing the medium, the efficacy of MicroGard 
products was not improved.  The pH of milk agar supplemented with MicroGard 
100 averaged 6.7, while agar supplemented with MicroGard 430 ranged from 
5.6—5.9.  Both pH values are much higher than the propionic acid pKa values, 
which would reduce the efficacy of the organic acid.  
Nisaplin, at the concentrations used in this study, delayed the growth of L. 
monocytogenes at the lower two inoculum levels in milk agar, but could not 
completely inhibit the organism.  Previously, nisin was shown to be ineffective in 
preventing the growth of L. innocua in a dairy-based system (Staszewski and 
Jagus, 2008).  Nisin initially reduced the count of the bacteria in liquid cheese 
whey (pH 5.5); however, the initial decrease was followed by immediate regrowth 
of the bacteria.  After 24 h of incubation at 25°C, L. innocua cell density from 
whey treated with nisin was not significantly different from control samples.  The 
authors hypothesized that the lack of antimicrobial effectiveness could be caused 
by the nonspecific binding of nisin to components of the milk agar.  Additionally, 
the concentration of active bacteriocin in Nisaplin potentially affected efficacy.  At 
the lower inoculum levels, the nisin concentration in milk agar was high enough 
to initially inhibit the growth.  However, there was not enough active bacteriocin in 
the medium to continuously inhibit growth.   
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VMY1P partially inhibited the growth of the three organisms tested. 
Though pH values in milk agar are similar to those in TSA, VMY1P provided 
inhibition in milk agar at concentrations where, in TSA, there had been no 
inhibition observed.  TSA is an ideal medium for the growth of the 
microorganisms tested.  Growth rates of the organisms in TSA most likely 
exceeded the degradation rates by the organic acids in VMY1P.  However, milk 
agar, since it is not as ideal an environment as TSA, provided another microbial 
hurdle for microorganisms and potentially increased the efficacy of VMY1P.  
The four antimicrobials that provided the most inhibition in TSA, NovaGard 
CB1, Protect-M, PuraQ Verdad RV75 and SEA-i F75, provided complete 
inhibition of the growth of E. coli O157:H7, Salmonella and L. monocytogenes in 
milk agar.  Changing the food matrix enhanced the effectiveness of the 
antimicrobials; the increased complexity of the agar made the conditions less 
favorable for microbial growth.  Under less favorable growth conditions, microbial 
growth rates slowed, allowing the antimicrobial system to work without being 
overwhelmed by rapid microbial growth.  Mechanisms for each antimicrobial 
were detailed in Chapter 3.  There was no antimicrobial activity of any of the 
sodium replacement agents detected in milk agar.  
 
4.6 Conclusion 
NovaGard CB1, Protect-M, PuraQ Verdad RV75 and SEA-i F75 were 
selected for further testing of antimicrobial efficacy in cheese agar and for 
potential antagonistic interactions with sodium replacement agents in milk agar.   
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5.0 Antimicrobial Efficacy Screening in Cheese Agar 
 
5.1 Objectives 
 To determine the antimicrobial efficacy of commercially available 
antimicrobials regular sodium and low sodium cheese agar. 
 
5.2 Hypothesis 
 Antimicrobial efficacy will not be reduced in regular and low sodium 
cheese agars. 
 
5.3 Materials and Methods 
 
5.3.1 Bacterial Strains 
  Five strains of each E. coli O157:H7, Listeria monocytogenes and 
Salmonella were used in the study.  E. coli O157:H7 strains NFPA 4212, NFPA 
4213, NFPA 4216, NFPA 4217, and NFPA 4219 were obtained from the culture 
collection of the National Food Laboratory (Livermore, CA).  Two of the Listeria 
monocytogenes strains, NFPA 6301 and NFPA 6306, were obtained from the 
culture collection of the National Food Laboratory (Livermore, CA) while the other 
three strains, NRRL B-33000, NRRL B-33096, and NRRL B-33113 were received 
from the National Center for Agricultural Utilization Research (Peoria, IL). 
Salmonella enterica strains, Salmonella Javiana FSL S5-406, Salmonella 
Enteriditis FSL S5-415, Salmonella Heidelburg FSL S5-448, Salmonella 
 70 
 
Oranienburg FSL S5-642, and Salmonella Typhimurium FSL W1-030, were 
obtained from the International Life Sciences Institute, North America (Cornell 
University, Ithaca, NY).  
 All strains were stored in cryogenic vials (Fisher Scientific, Hanover Park, 
IL) at -70°C for long-term preservation.  Prior to use, cultures were streaked on 
selective media and incubated at 35°C for 24 h.  Salmonella strains were 
streaked on Xylose Lysine Deoxycholate Agar (XLD, Neogen, Lansing, MI), while 
Modified Oxford Agar (MOX, Difco, Sparks, MD) was used for Listeria 
monocytogenes and MacConkey Agar with Sorbitol (SMAC, Neogen, Lansing, 
MI) was used for E. coli O157:H7.  Isolated colonies were used for inoculum 
preparation.  
 
5.3.2 Preparation of Inocula 
   Each strain was individually transferred into 10 ml of Tryptic Soy Broth 
(TSB, Neogen, Lansing, MI) and grown at 35°C for 18 h.  After incubation, equal 
volumes of each strain were pooled within a species to form a cocktail.  Each 
cocktail was centrifuged (1,800 g x 15 min), washed twice with 0.1% peptone 
water and resuspended in 0.1% peptone water.  Direct microscope count (DMC) 
was done with a Petroff-Hausser Counting Chamber (Hausser Scientific, 
Horsham, PA) to determine the initial stock concentration.  Cocktails were diluted 
to the target concentration using 0.1% peptone water.  Initial counts were 
confirmed by plating on Tryptic Soy Agar (TSA, Neogen, Lansing, MI) and 
incubating at 35°C for 24h.  
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5.3.3 Antimicrobials 
   Four antimicrobials received from several suppliers were used in the 
study and consisted of NovaGard CB1, Protect-M, PuraQ Verdad RV 75 and 
SEA-i F75(Table 5.1).  Antimicrobials were stored per manufacturer’s 
recommendation until used in the study.   
 
5.3.4 Antimicrobial Efficacy Determination 
   The efficacy of the antimicrobials in cheese agar was determined using 
an agar dilution method (Oussalah et al., 2007b).  Cheese agar was prepared by 
adding 28 g of either regular sodium or low sodium low-moisture part-skim 
mozzarella to 300 ml of sterile 1.5% agar.  Cheese was melted and dispersed in 
the agar prior to the addition of antimicrobials.  Antimicrobials were added to agar 
at one concentration; concentrations were determined using manufacturer 
recommendations and preliminary results in TSA and milk agar (Table 5.1).  The 
supplemented agars were poured into sterile petri plates and allowed to solidify.  
Salmonella, L. monocytogenes or E. coli O157:H7 was spread plated onto 
solidified cheese agar at a target concentration of 101, 102 and 104 CFU/ml.  
Uninoculated cheese agar plates served as negative controls while inoculated 
plates, without antimicrobial added, served as positive controls.  Uninoculated 
supplemented agar plates were also tested for pH.  All test and control plates 
were incubated at 35°C for 48 h.  Plates were observed after 24 h and 48 h for 
presence or absence of growth.  For all plates, absence of growth indicated the 
antimicrobial had an inhibitory effect. 
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Table 5.1 Description and concentrations of antimicrobials used in antimicrobial efficacy screening 
in regular sodium and low sodium cheese agars. 
Antimicrobial Manufacturer Product Description 
Concentration Used 
(%) 
    
NovaGard 
CB1 
Danisco 
Maltodextrin; Cultured Dextrose; Sodium 
Diacetate; NaCl; Lysozyme; Nisin 
1.0 
    
Protect-M Purac Lauric Arginate 0.20 
    
PuraQ Verdad 
RV75 
Purac 
Cultured Sugar; Organic Acids; Residual 
Sugars 
0.20 
    
SEA-i F75 Bienca 
Glucose; Glucose Oxidase; Whey; 
Lactoperoxidase; Lactose; Casein 
0.25 
    
 
 
5.4 Results 
  
5.4.1 Efficacy of Antimicrobials against Salmonella, E. coli O157:H7 and L. 
monocytogenes in Regular Sodium Cheese Agar.  
 NovaGard CB1 and PuraQ Verdad RV75 completely inhibited the growth 
of E. coli O157:H7 and Salmonella at the lowest inoculum level (Table 5.2).  All 
other test conditions with NovaGard CB1 and PuraQ Verdad RV75 yielded 
growth after 48 h of incubation.  At an inoculum level of 104 CFU/ml,  Protect-M 
provided no inhibition of the growth of E. coli O157:H7, L. monocytogenes or 
Salmonella.  At an inoculum level of 102 CFU/ml, Protect-M still did not inhibit 
Salmonella, but it completely inhibited the growth of E. coli O157:H7 and L. 
monocytogenes.  At an inoculum level of 101 CFU/ml, Protect-M delayed the 
growth of Salmonella and completely inhibited the growth E. coli O157:H7 and L 
monocytogenes.  SEA-i F75 provided complete inhibition of the three organisms 
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tested in regular sodium cheese agar, regardless of the inoculum level (Table 
5.2).   
Table 5.2 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 101, 
102 and 104 CFU/ml on regular sodium cheese agar supplemented with various antimicrobials after 
incubation at 35°C.  
Antimicrobial 
(concentration) 
Target Inoculum 
Level 
Time Until Observed Organism Growth  
Salmonella E. coli O157:H7 Listeria 
     
NovaGard CB1 (1.0%) 
(pH 5.39) 
101 CFU/ml NG1 48 h 48 h 
102 CFU/ml 48 h 48 h 48 h 
104 CFU/ml 48 h 48 h 48 h 
     
Protect-M (0.2%) 
(pH 4.96) 
101 CFU/ml 48 h NG NG 
102 CFU/ml 24 h NG NG 
104 CFU/ml 24 h 24 h 24 h 
     
PuraQ Verdad RV75 
(0.2%) 
(pH 4.84) 
101 CFU/ml NG 48 h 48 h 
102 CFU/ml 48 h 48 h 48 h 
104 CFU/ml 48 h 48 h 48 h 
     
SEA-i F75 (0.25%) 
(pH 4.96) 
101 CFU/ml NG NG NG 
102 CFU/ml NG NG NG 
104 CFU/ml NG NG NG 
     
1
NG: No growth detected after 48 h of incubation at 35°C. 
 
 
5.4.2 Efficacy of Antimicrobials against Salmonella, E. coli O157:H7 and L. 
monocytogenes in Low Sodium Cheese Agar 
  At an inoculum level of 101 CFU/ml, NovaGard CB1 provided complete 
inhibition of the growth of Salmonella, and delayed the growth of L. 
monocytogenes and E. coli O157:H7 (Table 5.3).  At higher inoculum levels, the 
growth of Salmonella, L. monocytogenes and E. coli O157:H7 was delayed.  
Protect-M completely inhibited the growth of Salmonella, L. monocytogenes, and 
E. coli O157:H7 at an inoculum level of 101 CFU/ml.  At an inoculum level of 102 
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CFU/ml, Protect-M provided complete inhibition of E. coli O157:H7 and L. 
momoncytogenes, but growth of Salmonella was detected after 48 h.  Growth of 
all three organisms was detected after 48 h at an inoculum level of 104 CFU/ml.  
At an inoculum level of 101 CFU/ml, PuraQ Verdad RV75 completely inhibited the 
growth of Salmonella and E. coli O157:H7 and delayed the growth of L. 
monocytogenes.  At higher inoculum levels, PuraQ Verdad RV75 delayed the 
growth of all three organisms.  SEA-i F75 completely inhibited the growth of 
Salmonella and E. coli O157: H7 at inoculum levels of 101 and 102 CFU/ml.  At 
104 CFU/ml, growth of both organisms was observed after 48 hours of 
incubation.  SEA-i F75 completely inhibited the growth of L. monocytogenes at 
every inoculum level tested. 
 
Table 5.3 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 101, 
102 and 104 CFU/ml on low sodium cheese agar supplemented with various antimicrobials after 
incubation at 35°C.  
Antimicrobial 
(concentration) 
Target Inoculum 
Level 
Time Until Observed Organism Growth  
Salmonella E. coli O157:H7 Listeria 
     
NovaGard CB1 (1.0%) 
(pH 5.42) 
101 CFU/ml NG1 48 h 48 h 
102 CFU/ml 48 h 48 h 48 h 
104 CFU/ml 48 h 48 h 48 h 
     
Protect-M (0.2%) 
(pH 4.98) 
101 CFU/ml NG NG NG 
102 CFU/ml 48 h NG NG 
104 CFU/ml 48 h 48 h 48 h 
     
PuraQ Verdad RV75 
(0.2%) 
(pH 4.87) 
101 CFU/ml NG NG 48 h 
102 CFU/ml 48 h 48 h 48 h 
104 CFU/ml 48 h 48 h 48 h 
     
SEA-i F75 (0.25%) 
(pH 4.94) 
101 CFU/ml NG NG NG 
102 CFU/ml NG NG NG 
104 CFU/ml 48 h 48 h NG 
     
1
NG: No growth detected after 48 h of incubation at 35°C. 
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5.5 Discussion 
 Efficacy of all four antimicrobials was reduced in cheese agars, as 
compared to milk agar (refer to Chapters 3 and 4 for results and antimicrobial 
mechanisms).  NovaGard CB1 was able to delay the growth of all three 
organisms tested in regular sodium and low sodium cheese agar.  Efficacy of 
lysozyme, a primary component of NovaGard CB1, can be limited by either the 
partial masking of the peptidoglycan substrate by cellular components or the 
incubation temperature (Hughey and Johnson, 1987).  Because of the greater 
complexity, the components of the cheese agar potentially restricted access to 
the peptidoglycan, limiting adhesion sites for lysozyme to bind and reducing the 
enzyme antimicrobial efficacy.  Additionally, the elevated incubation temperature 
allowed the rapidly growing cells to replenish the cells wall at rates much faster 
than the degradation of the cell wall by the lysozyme. 
 Protect-M was less effective in regular sodium cheese agar than in low 
sodium cheese agar.  Potency of lauric arginate (LAE) can be affected by 
interactions with the food matrix.  As a cationic surfactant, LAE may interact with 
anionic biopolymers in the food matrix through electrostatic interactions, causing 
reduction in activity (Asker et al., 2009).  As the chloride concentration 
decreased, LAE activity increased, suggesting that there may be some 
interaction between LAE and the chloride in the cheese formulations.  
 Though there was not a major increase in pH (as compared to milk agar), 
decreases in the efficacy of PuraQ Verdad RV75 were observed in cheese agar. 
Though pH is the major determinant of antimicrobial activity for PuraQ Verdad 
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RV75, competition for adhesion sites may have reduced efficacy.  The increased 
agar complexity likely contributed to the reduction in antimicrobial efficacy.  
 The efficacy of SEA-i F75 was unchanged in regular sodium cheese agar, 
but decreased in low sodium cheese agar.  Lactoperoxidase requires either 
thiocyanate or a halide, in addition to H2O2, in order to function as an 
antimicrobial.  In the presence of a halide, the enzyme will forego its use of 
thiocyanate and rely solely on the halide to function (Boots and Floris, 2006).  
The decrease in activity in low sodium cheese agar indicates that chloride was 
contributing to the function of lactoperoxidase.  
 
5.6 Conclusion 
Efficacies of all four antimicrobials were reduced in cheese agar, as 
compared to milk agar.  SEA-i F75 was the most effective antimicrobial in both 
cheese agars.  In order to determine if there were any interaction between the 
antimicrobials and the sodium replacement agents, combinations were tested in 
milk agar, where the greatest antimicrobial efficacy was observed.  
  
 77 
 
6.0 Antimicrobial and Sodium Replacement Agent Interaction Testing 
 
6.1 Objectives 
 To determine if sodium replacement agents would reduce antimicrobial 
efficacy in a dairy based system.  
 
6.2 Hypothesis 
 There will be no reductions in the efficacy of antimicrobials when 
combined with sodium replacement agents.  
 
6.3 Materials and Methods 
 
6.3.1 Bacterial Strains 
  Five strains of each E. coli O157:H7, Listeria monocytogenes and 
Salmonella were used in the study. E. coli O157:H7 strains NFPA 4212, NFPA 
4213, NFPA 4216, NFPA 4217, and NFPA 4219 were obtained from the culture 
collection of the National Food Laboratory (Livermore, CA).  Two of the Listeria 
monocytogenes strains, NFPA 6301 and NFPA 6306, were obtained from the 
culture collection of the National Food Laboratory (Livermore, CA) while the other 
three strains, NRRL B-33000, NRRL B-33096, and NRRL B-33113 were received 
from the National Center for Agricultural Utilization Research (Peoria, IL).  
Salmonella enterica strains, Salmonella Javiana FSL S5-406, Salmonella 
Enteriditis FSL S5-415, Salmonella Heidelburg FSL S5-448, Salmonella 
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Oranienburg FSL S5-642, and Salmonella Typhimurium FSL W1-030, were 
obtained from the International Life Sciences Institute, North America (Cornell 
University, Ithaca, NY).  
 All strains were stored in cryogenic vials (Fisher Scientific, Hanover Park, 
IL) at -70°C for long-term preservation.  Prior to use, cultures were streaked on 
selective media and incubated at 35°C for 24 h.  Salmonella strains were 
streaked on Xylose Lysine Deoxycholate Agar (XLD, Neogen, Lansing, MI), while 
Modified Oxford Agar (MOX, Difco, Sparks, MD) was used for Listeria 
monocytogenes and MacConkey Agar with Sorbitol (SMAC, Neogen, Lansing, 
MI) was used for E. coli O157:H7.  Isolated colonies were used for inoculum 
preparation.  
 
6.3.2 Preparation of Inocula 
  Each strain was individually transferred into 10 ml of Tryptic Soy Broth 
(TSB, Neogen, Lansing, MI) and grown at 35°C for 18 h.  After incubation, equal 
volumes of each strain were pooled within a species to form a cocktail.  Each 
cocktail was centrifuged (1,800 g x 15 min), washed twice with 0.1% peptone 
water and resuspended in 0.1% peptone water.  Direct microscope count (DMC) 
was done with a Petroff-Hausser Counting Chamber (Hausser Scientific, 
Horsham, PA) to determine the initial stock concentration.  Cocktails were diluted 
to the target concentration using 0.1% peptone water.  Initial counts were 
confirmed by plating on Tryptic Soy Agar (TSA, Neogen, Lansing, MI) and 
incubating at 35°C for 24h.  
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6.3.3 Antimicrobials and Sodium Replacement Agents. 
  Four antimicrobials received from several suppliers were used in the 
study and consisted of NovaGard CB1, Protect-M, PuraQ Verdad RV 75 and 
SEA-i F75 (Table 6.1).  Eight sodium replacement agents received from several 
suppliers were also used in the study (Table 2).  These included Alta 2345, 
potassium chloride, Puracal PP/USP, PuraQ Verdad NV10, Purasal Hi Pure P 
Plus, Salona, SaltWise 0029 and SaltWise 1029.  Antimicrobials and sodium 
replacement agents were stored per manufacturer’s recommendation until used 
in the study.   
 
6.3.4 Antimicrobial Interaction Testing.   
 An agar dilution method was used to test for an interaction between 
antimicrobials and sodium replacement agents in TSA and milk agar (Oussalah 
et al., 2007b).  TSA was prepared per manufacturer’s preparation instructions, 
then adjusted to pH 5.8 using 1N HCl.  Milk agar was prepared by dissolving 
nonfat dry milk (8 g/L) and agar (15 g/L) in deionized water.  Agar was 
autoclaved at 121°C for 15 minutes then tempered prior to use.  One 
concentration of each antimicrobial was added to either TSA or milk agar.  
Sodium replacement agents were then added to supplemented agar at one or 
two concentrations (Tables 6.1 and 6.2).  TSA and milk agar, supplemented with 
a sodium replacement agent and an antimicrobial, were poured into sterile petri 
plates and allowed to solidify.  Concentrations used for each antimicrobial and 
sodium replacement agent were determined using manufacturer 
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recommendations and preliminary antimicrobial efficacy results in TSA and milk 
agar.  
 Salmonella, L. monocytogenes or E. coli O157:H7 was spread plated onto 
solidified TSA or milk agar at a target concentration of 104 CFU/ml.  Uninoculated 
TSA and milk agar plates served as negative controls while inoculated plates, 
without antimicrobial added, served as positive controls.  All test and control 
plates were incubated at 35°C for 48 h.  Plates were observed after 24 h and 48 
h for presence or absence of growth.  For all plates, a change in growth, as 
compared to previous antimicrobial results without salt substitutes, indicated an 
interaction between the antimicrobial and the sodium reduction agent.  
 
Table 6.1 Description and concentrations of antimicrobials used in interaction testing in TSA and 
milk agar. 
Antimicrobial Manufacturer Product Description 
Concentration Used 
(%) 
    
NovaGard 
CB1 
Danisco 
Maltodextrin; Cultured Dextrose; Sodium 
Diacetate; NaCl; Lysozyme; Nisin 
1.0 
    
Protect-M Purac Lauric Arginate 0.20 
    
PuraQ Verdad 
RV75 
Purac 
Cultured Sugar; Organic Acids; Residual 
Sugars 
0.20 
    
SEA-i F75 Bienca 
Glucose; Glucose Oxidase; Whey; 
Lactoperoxidase; Lactose; Casein 
0.25 
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Table 6.2 Description and concentrations of sodium replacement agents used in interaction testing 
in TSA and milk agar. 
 
6.4 Results 
 
6.4.1 NovaGard CB1 
 Results in TSA showed that NovaGard CB1 alone could not inhibit the 
growth of the three organisms tested (Table 6.3).  When combined with sodium 
replacement agents that did not contain KCl, antimicrobial efficacy of NovaGard 
CB1 increased.  In milk agar, NovaGard CB1 completely inhibited the growth of 
Sodium 
Replacement Agents 
Manufacture
r 
Product Description 
Concentrations Used 
(%) 
TSA Milk Agar 
      
Alta 2345 Kerry Yeast Extract 0.25 0.25  
      
Potassium Chloride Cargill Potassium chloride 2.0 1.0 2.0 
      
Puracal PP/USP Purac Calcium lactate 0.04 0.02 0.04 
      
Purasal Hi Pure P 
Plus 
Purac Potassium lactate 0.04 0.02 0.04 
      
PuraQ Verdad NV10 Purac Cultured corn sugar 0.04 0.02 0.04 
      
Salona BK Giulini 
Reduced sodium sea salt from Dead 
Sea 
0.95 0.95  
      
SaltWise 0029 Cargill 
Potassium chloride; trehalose; 
autolyzed yeast extract; silicon 
dioxide 
2.0 1.0 2.0 
      
SaltWise 1029 Cargill 
Potassium chloride; trehalose; 
autolyzed yeast extract; silicon 
dioxide 
2.0 1.0 2.0 
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the three organisms tested when no sodium replacement agent was added 
(Table 6.4).  Reductions in efficacy were observed when NovaGard CB1 was 
combined with sodium replacement agents that contained KCl.  
 
6.4.2 Protect-M.  
Growth of all three organisms was completely inhibited in TSA 
supplemented with Protect-M and any of the sodium replacement agents used 
(Table 6.5).  In milk agar, L. monoycytogenes growth was completely inhibited by 
Protect-M, regardless of the sodium replacement agent combination (Table 6.6).  
The antimicrobial efficacy of Protect-M against E. coli O157:H7 remained the 
same when the antimicrobial was combined with Alta 2345 and the lowest 
concentration of KCl.  All other test conditions eventually yielded growth of the 
organism.  Inhibition of Salmonella was only observed when Protect-M was 
combined with the lowest concentration of KCl.  Growth was observed in all other 
test conditions within 48 h.  
 
6.4.3 PuraQ Verdad RV75 
 Antimicrobial efficacy of PuraQ Verdad RV75 in TSA was not affected by 
the addition of sodium replacement agents; growth was still observed after 24 h 
of incubation (Table 6.7).  In milk agar, L. monoycytogenes growth was 
completely inhibited by PuraQ Verdad RV75, regardless of the sodium 
replacement agent combination (Table 6.8).  Decreases in efficacy of PuraQ 
Verdad RV75 against E. coli O157:H7 were observed when the antimicrobial was 
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tested in combination with Purasal Hi Pure P Plus.  All other conditions yielded 
growth of E. coli O157:H7 within 48 h.  Growth of Salmonella was not observed 
when PuraQ Verdad RV75 was tested in combination with Salona.  However, 
when combined with any of the other sodium replacement agents, antimicrobial 
activity was reduced.  
 
6.4.4 SEA-i F75 
 No growth of any of the organisms tested was observed in TSA or milk 
agar supplemented with SEA-i F75 and any of the sodium replacement agents 
(Tables 6.9 and 6.10).  
Table 6.3 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 104 
CFU/ml on TSA (pH 5.8) supplemented with NovaGard CB1 at a concentration of 1.0% and 
various sodium replacement agents after incubation at 35°C. 
Sodium Replacement Agent Time Until Observed Organism Growth 
Name 
Concentration 
(%) 
Salmonella E. coli O157:H7 
L. 
monocytogenes 
     
No Sodium Replacer NA 24 h 24 h 24 h 
     
Alta 2345 0.25 48 h 24 h 48 h 
     
Potassium Chloride 2.0 24 h 24 h 24 h 
     
Puracal PP/USP 0.04 48 h 48 h 48 h 
     
Purasal Hi Pure P 
Plus 
0.04 NG1 NG NG 
     
PuraQ Verdad NV10 0.04 48 h 48 h 48 h 
     
Salona 0.95 48 h 24 h 48 h 
     
SaltWise 0029 2.0 24 h 24 h 24 h 
     
SaltWise 1029 2.0 24 h 24 h 24 h 
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 6.4 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 104 
CFU/ml on milk agar supplemented with NovaGard CB1 at a concentration of 1.0% and various 
sodium replacement agents after incubation at 35°C. 
Sodium Replacement Agent Time Until Observed Organism Growth 
Name 
Concentration 
(%) 
Salmonella E. coli O157:H7 
L. 
monocytogenes 
     
No Sodium 
Replacer 
NA NG1 NG NG 
     
Alta 2345 0.25 NG1 NG NG 
     
Potassium Chloride 
1.0 NG NG NG 
2.0 24 h 24 h NG 
     
Puracal PP/USP 
0.02 NG NG NG 
0.04 NG NG NG 
     
Purasal Hi Pure P 
Plus 
0.02 NG NG NG 
0.04 NG NG NG 
     
PuraQ Verdad 
NV10 
0.02 NG NG NG 
0.04 NG NG NG 
     
Salona 0.95 NG NG NG 
     
SaltWise 0029 
1.0 NG NG NG 
2.0 24 h 24 h NG 
     
SaltWise 1029 
1.0 NG NG NG 
2.0 24 h 24 h NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 6.5 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 104 
CFU/ml on TSA (pH 5.8) supplemented with Protect-M at a concentration of 0.2% and various 
sodium replacement agents after incubation at 35°C. 
Sodium Replacement Agent Time Until Observed Organism Growth 
Name 
Concentration 
(%) 
Salmonella E. coli O157:H7 
L. 
monocytogenes 
     
No Sodium Replacer NA NG1 NG NG 
     
Alta 2345 0.25 NG NG NG 
     
Potassium Chloride 2.0 NG NG NG 
     
Puracal PP/USP 0.04 NG NG NG 
     
Purasal Hi Pure P 
Plus 
0.04 NG NG NG 
     
PuraQ Verdad NV10 0.04 NG NG NG 
     
Salona 0.95 NG NG NG 
     
SaltWise 0029 2.0 NG NG NG 
     
SaltWise 1029 2.0 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 6.6 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 104 
CFU/ml on milk agar supplemented with Protect-M at a concentration of 0.2% and various sodium 
replacement agents after incubation at 35°C. 
Sodium Replacement Agent Time Until Observed Organism Growth 
Name Concentration (%) Salmonella 
E. coli 
O157:H7 
L. 
monocytogenes 
     
No Sodium 
Replacer 
NA NG1 NG NG 
     
Alta 2345 0.25 48 h NG NG 
     
Potassium Chloride 
1.0 NG NG NG 
2.0 24 h 48 h NG 
     
Puracal PP/USP 
0.02 24 h 24 h NG 
0.04 24 h 24 h NG 
     
Purasal Hi Pure P 
Plus 
0.02 24 h 24 h NG 
0.04 24 h 24 h NG 
     
PuraQ Verdad 
NV10 
0.02 24 h 24 h NG 
0.04 24 h 24 h NG 
     
Salona 0.95 24 h 24 h NG 
     
SaltWise 0029 
1.0 24 h 24 h NG 
2.0 24 h 48 h NG 
     
SaltWise 1029 
1.0 24 h 24 h NG 
2.0 24 h 48 h NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 6.7 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 104 
CFU/ml on TSA (pH 5.8) supplemented with PuraQ Verdad RV75 at a concentration of 0.2% and 
various sodium replacement agents after incubation at 35°C. 
Sodium Replacement Agent Time Until Observed Organism Growth 
Name 
Concentration 
(%) 
Salmonella E. coli O157:H7 
L. 
monocytogenes 
     
No Sodium Replacer NA 24 h 24 h 24 h 
     
Alta 2345 0.25 24 h 24 h 24 h 
     
Potassium Chloride 2.0 24 h 24 h 24 h 
     
Puracal PP/USP 0.04 24 h 24 h 24 h 
     
Purasal Hi Pure P 
Plus 
0.04 24 h 24 h 24 h 
     
PuraQ Verdad NV10 0.04 24 h 24 h 24 h 
     
Salona 0.95 24 h 24 h 24 h 
     
SaltWise 0029 2.0 24 h 24 h 24 h 
     
SaltWise 1029 2.0 24 h 24 h 24 h 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 6.8 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 104 
CFU/ml on milk agar supplemented with PuraQ Verdad RV75 at a concentration of 0.2% and 
various sodium replacement agents after incubation at 35°C. 
Sodium Replacement Agent Time Until Observed Organism Growth 
Name 
Concentration 
(%) 
Salmonella E. coli O157:H7 
L. 
monocytogenes 
     
No Sodium 
Replacer 
NA NG NG NG 
     
Alta 2345 0.25 48 h 48 h NG1 
     
Potassium Chloride 
1.0 48 h NG NG 
2.0 24 h 24 h NG 
     
Puracal PP/USP 
0.02 48 h NG NG 
0.04 48 h  48 h NG 
     
Purasal Hi Pure P 
Plus 
0.02 48 h NG NG 
0.04 48 h NG NG 
     
PuraQ Verdad 
NV10 
0.02 48 h NG NG 
0.04 48 h 48 h NG 
     
Salona 0.95 NG 48 h NG 
     
SaltWise 0029 
1.0 48 h NG NG 
2.0 24 h 24 h NG 
     
SaltWise 1029 
1.0 48 h NG NG 
2.0 24 h 24 h NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 6.9 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 104 
CFU/ml on TSA (pH 5.8) supplemented with SEA-i F75 at a concentration of 0.25% and various 
sodium replacement agents after incubation at 35°C. 
Sodium Replacement Agent Time Until Observed Organism Growth 
Name 
Concentration 
(%) 
Salmonella E. coli O157:H7 
L. 
monocytogenes 
     
No Sodium Replacer NA NG1 NG NG 
     
Alta 2345 0.25 NG NG NG 
     
Potassium Chloride 2.0 NG NG NG 
     
Puracal PP/USP 0.04 NG NG NG 
     
Purasal Hi Pure P 
Plus 
0.04 NG NG NG 
     
PuraQ Verdad NV10 0.04 NG NG NG 
     
Salona 0.95 NG NG NG 
     
SaltWise 0029 2.0 NG NG NG 
     
SaltWise 1029 2.0 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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Table 6.10 Growth of Salmonella, E. coli O157:H7 and L. monocytogenes at concentrations of 104 
CFU/ml on milk agar supplemented with SEA-i F75 at a concentration of 0.25% and various 
sodium replacement agents after incubation at 35°C. 
Sodium Replacement Agent Time Until Observed Organism Growth 
Name 
Concentration 
(%) 
Salmonella E. coli O157:H7 
L. 
monocytogenes 
     
No Sodium 
Replacer 
NA NG1 NG NG 
     
Alta 2345 0.25 NG NG NG 
     
Potassium Chloride 
1.0 NG NG NG 
2.0 NG NG NG 
     
Puracal PP/USP 
0.02 NG NG NG 
0.04 NG NG NG 
     
Purasal Hi Pure P 
Plus 
0.02 NG NG NG 
0.04 NG NG NG 
     
PuraQ Verdad 
NV10 
0.02 NG NG NG 
0.04 NG NG NG 
     
Salona 0.95 NG NG NG 
     
SaltWise 0029 
1.0 NG NG NG 
2.0 NG NG NG 
     
SaltWise 1029 
1.0 NG NG NG 
2.0 NG NG NG 
     
1NG: No growth detected after 48 hours of incubation at 35°C. 
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6.5 Discussion 
 There was no reduction in the antimicrobial efficacy of NovaGard CB1 in 
TSA when combined with any of the sodium replacement agents.  The 
antimicrobial efficacy of NovaGard CB1 was reduced by sodium replacement 
agents that contained KCl in milk agar.  Efficacy of lysozyme, one of the major 
antimicrobial components of NovaGard CB1, can be reduced with increases in 
cation concentrations (Branen and Davidson, 2004).  It is reasonable to assume 
that the changes in efficacy were caused by interactions between the lysozyme 
in the NovaGard and potassium chloride.  The increase in K+ concentration in the 
agar systems potentially reduced the efficacy of NovaGard CB1.  
 Although no decreases in the efficacy of Protect-M were observed in TSA, 
efficacy against Salmonella and E. coli O157:H7 was reduced in milk agar.  
Potency of LAE can be reduced in the presence of anionic biopolymers 
(Rodriguez et al, 2004).  Salts, lactates and other organic acids could potentially 
dissociate in agar and produce anionic biopolymers.  Interactions between these 
anionic components and LAE potentially led to reductions in efficacy.  
 Though antimicrobial activity of Pura Verdad RV75 relies heavily on the 
pH value, the pH value did not vary greatly between milk agars supplemented 
with PuraQ Verdad RV75 and sodium replacement agents (data not shown).  
Therefore differences in antimicrobial activity cannot be attributed to differences 
in pH.  Sodium replacement agents could have potentially obstructed access of 
PuraQ Verdad RV75 to adhesion sites on the cellular membrane, thereby 
reducing antimicrobial efficacy.  
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There were no antagonistic interactions between SEA-i F75 and any of the 
sodium replacement agents observed.  No decreases in antimicrobial activity 
were detected regardless of the combination.  Antimicrobial activity of SEA-i F75 
depends on the presence of hydrogen peroxide and the concentration of 
thiocyanate in the milk agar, which do not change with the addition of sodium 
replacement agents.  
 
6.6 Conclusion 
 SEA-i F75 was the only antimicrobial tested whose efficacy was not 
reduced with the addition of a sodium replacement agent.  The overall 
effectiveness of SEA-i F75 in different media led to the selection of this 
antimicrobial for use in a low sodium low-moisture part-skim (LMPS) mozzarella 
cheese.  
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7.0 Final Cheese Challenge 
 
7.1 Objective 
 To determine the fate of Salmonella, Listeria monocytogenes and E. coli 
0157:H7 in six formulations of artificially inoculated regular sodium and low 
sodium low-moisture part-skim (LMPS) mozzarella string cheese with and 
without the addition of sodium replacements and SEA-i F75. 
 
7.2 Hypothesis 
 SEA-i F75 will inhibit the growth of Salmonella, L. monocytogenes and E. 
coli O157:H7 in all formulations tested during incubation at 4° and 12°C for 30 
and 90 days, respectively. 
 
7.3 Materials and Methods 
 
7.3.1 Bacterial Strains 
  Five strains of each E. coli O157:H7, Listeria monocytogenes and 
Salmonella were used in the study.  E. coli O157:H7 strains NFPA 4212, NFPA 
4213, NFPA 4216, NFPA 4217, and NFPA 4219 were obtained from the culture 
collection of the National Food Laboratory (Livermore, CA).  Two of the Listeria 
monocytogenes strains, NFPA 6301 and NFPA 6306, were obtained from the 
culture collection of the National Food Laboratory (Livermore, CA) while the other 
three strains, NRRL B-33000, NRRL B-33096, and NRRL B-33113 were received 
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from the National Center for Agricultural Utilization Research (Peoria, IL).  
Salmonella enterica strains, Salmonella Javiana FSL S5-406, Salmonella 
Enteriditis FSL S5-415, Salmonella Heidelburg FSL S5-448, Salmonella 
Oranienburg FSL S5-642, and Salmonella Typhimurium FSL W1-030, were 
obtained from the International Life Sciences Institute, North America (Cornell 
University, Ithaca, NY).  
 All strains were stored in cryogenic vials (Fisher Scientific, Hanover Park, 
IL) at -70°C for long-term preservation.  Prior to use, cultures were streaked on 
selective media and incubated at 35°C for 24 h.  Salmonella strains were 
streaked on Xylose Lysine Deoxycholate Agar (XLD, Neogen, Lansing, MI), while 
Modified Oxford Agar (MOX, Difco, Sparks, MD) was used for Listeria 
monocytogenes and MacConkey Agar with Sorbitol (SMAC, Neogen, Lansing, 
MI) was used for E. coli O157:H7.  Isolated colonies were used for inoculum 
preparation.  
 
7.3.2 Preparation of Inocula 
 Each strain was individually transferred into 10 ml of Tryptic Soy Broth 
(TSB, Neogen, Lansing, MI) and grown at 35°C for 18 h.  After incubation, equal 
volumes of each strain were pooled within a species to form a cocktail.  Each 
cocktail was centrifuged (1,800 g x 15 min), washed twice with 0.1% peptone 
water and resuspended in 0.1% peptone water.  Direct microscope count (DMC) 
was done with a Petroff-Hausser Counting Chamber (Hausser Scientific, 
Horsham, PA) to determine the initial stock concentration.  Cocktails were diluted 
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to the target concentration using 0.1% peptone water.  Initial counts were 
confirmed by plating on Tryptic Soy Agar (TSA, Neogen, Lansing, MI) and 
incubating at 35°C for 24h.  
 
7.3.3 Antimicrobials and Sodium Replacement Agents 
 Antimicrobial SEA-i F75 was received from Bienca and stored refrigerated 
until use.  SEA-i F75 was used at a concentration of 0.25% in all treatments.  
Three sodium replacement agents received from several suppliers were also 
used in the study; Alta 2345, potassium chloride, and Salona were used a 
concentrations of 0.25%, 1.0% and 0.95%, respectively.  Sodium replacement 
agents were stored at ambient temperature until use.    
 
7.3.4 Product Formulations and Preparation 
 Six formulations of low-moisture part-skim mozzarella cheese were 
produced at the Dairy Products Technology Center and used in the study (Table 
7.3).  An antimicrobial dip was produced using sterile DI water and SEA-i F75 at 
a concentration of 0.25%.  Prior to inoculation, four of the cheese formulations, 
low sodium treated, NaCl/KCl combination, NaCl/Alta 2345 combination and 
NaCl/Salona combination, were dipped in the antimicrobial solution for two 
minutes.  After dipping, cheese pieces were allowed to dry for thirty minutes in a 
biosafety cabinet before inoculation.  Regular sodium and low sodium untreated 
cheeses served as positive controls.  
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Table 7.1 Formulations of low-moisture part-skim mozzarella cheese used in the final cheese 
challenge study. 
Formulation Salt (NaCl) Content Dipped in Antimicrobial (Y/N) 
   
Regular Sodium  1.7% No 
Low Sodium Untreated 0.7% No 
Low Sodium Treated 0.7% Yes 
NaCl/KCl Combination 0.7% Yes 
NaCl/Alta 2345 Combination 0.7% Yes 
NaCl/Salona Combination 0.7% Yes 
   
 
7.3.5 Product Inoculation and Incubation 
Fifteen gram pieces of cheese from each formulation were inoculated with 
30 µl of Salmonella, Listeria monocytogenes or E. coli 0157:H7 cocktails at a 
target concentration of 102–103 CFU/g.  Uninoculated product served as a 
negative control.  The cocktail was allowed to dry for one hour then product was 
transferred to bags, vacuum-sealed and incubated at 4° or 12°C.  Samples 
incubated at 4°C were tested after 0, 1, 7, 15 and 35 days of incubation, while 
samples incubated at 12°C were tested after 0, 1, 3, 7, 14, and 35 days of 
incubation.  The experiment was repeated three times. 
 
7.3.6 Sample Pulls and Enumeration 
At each pull time, three inoculated samples and two uninonculated 
samples of each formulation were pulled from the incubator and diluted with 
0.1% peptone water.  Inoculated samples were tested for either L. 
monocytogenes, Salmonella or E. coli O157:H7.  Uninoculated samples were 
tested, in duplicate, for coliforms, yeast, mold, psychrotrophs, pH and water 
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activity.  Samples were enumerated, in duplicate, on selective media and 
incubated for 48 h.  Xylose Lysine Deoxycholate Agar (XLD), MacConkey Agar 
with Sorbitol (SMAC), and Modified Oxford Agar (MOX) were used for 
enumeration of Salmonella, E. coli O157:H7 and L. monocytogenes, respectively.  
Colonies exhibiting the typical morphologies/reactions of each organism were 
counted as the organism.  No other confirmations were performed.  
 
7.4 Results 
 There were major flaws in the execution of this study.  In the first 
experimental trial, expired SEA-i F75 was used in the treated samples.  
Additional efficacy screenings in TSA and milk agar showed that the antimicrobial 
activity of the enzyme had not reduced after expiration.  However, the validity of 
results obtained through the use of expired enzyme is questionable.  Results 
from second and third experimental trials were combined.  Though unexpired 
SEA-i F75 was used in the second and third experimental trials, cheeses used in 
both trials had high counts of spoilage microorganisms.  
 
7.4.1 Preliminary Analysis 
Water activity and pH values of the six formulations over all trials were 
combined and averaged.  Initial pH values were similar across all six 
formulations, ranging from 5.39—5.52.  During incubation, pH values increased 
in samples incubated at 4°C and decreased in samples incubated at 12°C for all 
formulations.  Water activity values were also similar across all formulations.  
 98 
 
However, the water activity of regular sodium cheese was slightly lower than that 
of the low sodium formulations.  Initial water activity in regular sodium cheeses 
averaged 0.9823 while water activity values for low sodium cheeses ranged from 
0.9908—0.9953. 
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Table 7.2  Average pH and water activity values for uninoculated samples of six formulations of low-moisture part-skim (LMPS) mozzarella cheese after incubation 
at 4° and 12°C. 
 Cheese Formulation 
Pull Date Regular Sodium Low Sodium Untreated Low Sodium Treated NaCl/KCl Combination NaCl/Alta Combination 
NaCl/Salona 
Combination 
 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 
             
Day 0             
pH±SD 5.52±0.08 5.52±0.08 5.42±0.17 5.42±0.17 5.46±0.26 5.46±0.26 5.48±0.13 5.48±0.13 5.39±0.22 5.39±0.22 5.43±0.19 5.43±0.19 
aw 0.9823 0.9823 0.9908 0.9908 0.9913 0.9913 0.9902 0.9902 0.9953 0.9953 0.9934 0.9934 
             
Day 1             
pH±SD 5.58±0.14 5.44±0.18 5.63±0.16 5.56±0.10 5.65±0.21 5.61±0.09 5.61±0.18 5.44±0.19 5.46±0.50 5.48±0.34 5.53±0.24 5.38±0.38 
aw 0.9827 0.9815 0.9897 0.9919 0.9919 0.9903 0.9907 0.9903 0.9931 0.9926 0.9924 0.9901 
             
Day 3             
pH±SD NT 5.34±0.29 NT 5.34±0.32 NT 5.45±0.37 NT 5.40±0.34 NT 5.43±0.42 NT 5.40±0.30 
aw NT 0.9824 NT 0.9909 NT 0.9930 NT 0.9912 NT 0.9943 NT 0.9926 
             
Day 7             
pH±SD 5.57±0.35 5.31±0.32 5.69±0.34 5.23±0.45 5.65±0.38 5.27±0.52 5.75±0.26 5.22±0.44 5.49±0.54 5.08±0.42 5.57±0.42 5.18±0.47 
aw 0.9830 0.9830 0.9919 0.9896 0.9925 0.9908 0.9918 0.9901 0.9942 0.9931 0.9933 0.9912 
             
Day 15             
pH±SD 5.70±0.13 5.02±0.32 5.67±0.31 5.08±0.39 5.72±0.28 5.13±0.33 5.65±0.38 5.01±0.24 5.55±0.48 4.84±0.17 5.65±0.30 4.92±0.27 
aw 0.9840 0.9790 0.9908 0.9869 0.9924 0.9882 0.9912 0.9881 0.9930 0.9903 0.9915 0.9889 
             
Day 35             
pH±SD 6.43±0.04 4.93±0.01 6.39±0.03 5.07±0.07 6.46±0.13 5.21±0.28 6.78±0.11 4.93±0.02 6.80±0.02 5.43±0.13 6.47±0.02 5.03±0.19 
aw 0.9829 0.9803 0.9904 0.9881 0.9897 0.9883 0.9909 0.9873 0.9933 0.9905 0.9927 0.9880 
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Table 7.3  Average coliform, yeast, mold and psychrotroph counts (log CFU/g) for uninoculated samples of six formulations of low-moisture part-skim (LMPS) 
mozzarella cheese after incubation at 4° and 12°C (Trial 1). 
Pull Date 
Regular Sodium Low Sodium Untreated Low Sodium Treated NaCl/KCl Combination NaCl/Alta Combination NaCl/Salona Combination 
4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 
             
Day 0             
Coliforms 1.65 1.65 3.93 3.93 <1 <1 2.53 2.53 <1 <1 <1 <1 
Yeast  1.24 1.24 1.81 1.81 <1 <1 1.48 1.48 1.51 1.51 <1 <1 
Mold <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 
Psychrotrophs 3.60 3.60 4.22 4.22 1.76 1.76 4.10 4.10 4.60 4.60 3.03 3.03 
Day 1             
Coliforms 2.22 <1 <1 1.51 <1 0.70 0.40 2.73 3.98 3.58 <1 2.07 
Yeast  2.32 <1 <1 0.70 <1 0.40 1.18 3.32 <1 <1 <1 <1 
Mold <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 
Psychrotrophs 4.36 2.91 0.70 4.48 1.97 3.04 2.87 4.57 <1 <1 <1 <1 
Day 3             
Coliforms NT 2.95 NT 2.50 NT 1.63 NT 2.93 NT 2.84 NT <1 
Yeast  NT <1 NT <1 NT <1 NT <1 NT 1.83 NT 1.63 
Mold NT <1 NT <1 NT <1 NT <1 NT <1 NT <1 
Psychrotrophs NT 4.61 NT 3.09 NT 4.55 NT 4.40 2.94 2.94 NT 4.47 
Day 7             
Coliforms 0.40 3.03 0.70 0.70 1.86 3.37 <1 <1 1.65 <1 <1 1.92 
Yeast  <1 <1 <1 <1 <1 1.35 <1 <1 2.69 3.26 2.41 <1 
Mold <1 1.88 <1 <1 <1 <1 1.24 <1 <1 <1 <1 <1 
Psychrotrophs 4.34 4.20 2.36 2.47 3.46 4.34 3.95 3.26 2.59 3.01 2.78 2.95 
Day 15             
Coliforms 3.17 3.78 0.88 2.68 2.33 2.35 2.74 2.70 2.82 3.43 2.73 1.57 
Yeast  <1 0.88 <1 <1 <1 <1 <1 1.24 <1 <1 <1 <1 
Mold <1 2.04 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 
Psychrotrophs 3.96 3.74 2.38 2.35 3.84 4.30 4.85 4.21 4.34 4.81 4.56 4.79 
Day 35             
Coliforms 5.65 5.33 0.70 5.65 5.46 2.97 4.32 4.27 5.14 5.94 3.99 5.53 
Yeast  <1 2.51 <1 <1 <1 <1 <1 1.48 <1 <1 <1 <1 
Mold 1.92 2.11 1.80 <1 2.76 0.40 <1 1.00 3.26 <1 <1 <1 
Psychrotrophs 5.17 5.37 3.22 <1 4.20 4.14 5.80 5.08 6.10 6.22 5.89 6.39 
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Table 7.4  Average coliform, yeast, mold and psychrotroph counts (log CFU/g) for uninoculated samples of six formulations of low-moisture part-skim (LMPS) 
mozzarella cheese after incubation at 4° and 12°C (Trials 2 and 3). 
Pull Date 
Regular Sodium Low Sodium Untreated Low Sodium Treated NaCl/KCl Combination NaCl/Alta Combination 
NaCl/Salona 
Combination 
4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 
             
Day 0             
Coliforms 5.72 5.72 5.89 5.89 5.15 5.15 4.12 4.12 4.91 4.91 4.22 4.22 
Yeast  1.33 1.53 3.96 3.96 1.38 1.38 2.14 2.14 2.53 2.53 1.00 1.00 
Mold 2.77 2.77 1.24 1.24 2.03 2.03 2.98 2.98 3.34 3.34 1.81 1.81 
Psychrotrophs 4.74 4.74 4.64 4.64 4.87 4.87 5.02 5.02 4.13 4.13 4.30 4.30 
             
Day 1             
Coliforms 4.49 4.94 4.73 5.31 4.38 4.27 4.00 4.22 3.99 4.13 3.64 4.09 
Yeast  <1 2.73 2076 2.40 2.81 3.39 0.70 2.95 3.77 3.13 2.26 3.40 
Mold 2.54 2.90 2.49 2.33 1.21 0.40 2.58 3.15 2.97 3.38 3.11 3.34 
Psychrotrophs 5.37 5.31 5.46 5.23 5.61 4.81 4.86 4.64 4.61 4.23 4.85 4.50 
             
Day 3             
Coliforms NT 5.36 NT 5.58 NT 5.50 NT 4.94 NT 4.06 NT 4.43 
Yeast  NT 1.10 NT 1.35 NT 1.74 NT 0.88 NT 1.00 NT 2.19 
Mold NT 2.98 NT 1.71 NT 2.80 NT 3.28 NT 3.49 NT 3.38 
Psychrotrophs NT 5.55 NT 5.35 NT 5.66 NT 3.53 NT 3.96 NT 4.17 
             
Day 7             
Coliforms 4.60 5.40 4.83 5.40 4.57 5.13 4.12 4.94 3.7 4.59 3.90 4.12 
Yeast  3.34 2.98 2.60 3.08 2.15 2.60 3.35 3.03 2.13 1.14 2.56 2.99 
Mold 3.17 3.42 2.74 2.12 1.56 3.16 3.34 3.27 3.44 3.62 3.25 3.46 
Psychrotrophs 4.82 4.41 4.21 4.62 4.89 3.99 4.83 4.05 4.84 5.16 4.59 4.60 
             
Day 15             
Coliforms 4.50 5.26 4.50 5.35 4.56 5.30 4.41 5.21 3.52 4.51 3.52 4.60 
Yeast  4.31 4.35 3.66 4.01 3.66 3.83 4.39 4.11 4.07 4.61 3.71 4.45 
Mold 3.30 3.37 3.06 3.12 2.11 2.91 3.24 3.35 3.38 3.63 3.29 3.43 
Psychrotrophs 5.70 3.65 4.79 3.85 4.70 4.40 4.97 4.03 5.21 4.46 4.88 3.81 
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Figure 7.1 Behavior of L. monocytogenes in six formulations of low-moisture part-
skim (LMPS) mozzarella cheese during incubation at 4°C (Trial 1).  
 
 
 
 
Figure 7.2 Behavior of L. monocytogenes in six formulations of low-moisture part-
skim (LMPS) mozzarella cheese during incubation at 4°C (Trials 2 and 3).   
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Figure 7.3 Behavior of L. monocytogenes in six formulations of low-moisture part-
skim (LMPS) mozzarella cheese during incubation at 12°C (Trial 1).  
 
 
Figure 7.4 Behavior of L .monocytogenes in six formulations of low-moisture part-
skim (LMPS) mozzarella cheese during incubation at 12°C (Trials 2 and 3).  
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Figure 7.5 Behavior of Salmonella in six formulations of low-moisture part-skim 
(LMPS) mozzarella cheese during incubation at 4°C (Trial 1).  
 
 
 
 
Figure 7.6 Behavior of Salmonella in six formulations of low-moisture part-skim 
(LMPS) mozzarella cheese during incubation at 4°C (Trials 2 and 3).  
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Figure 7.7 Behavior of Salmonella in six formulations of low-moisture part-skim 
(LMPS) mozzarella cheese during incubation at 12°C (Trial 1).  
 
 
Figure 7.8 Behavior of Salmonella in six formulations of low-moisture part-skim 
(LMPS) mozzarella cheese during incubation at 12°C (Trials 2 and 3).
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Figure 7.9 Behavior of E. coli O157:H7 in six formulations of low-moisture part-
skim (LMPS) mozzarella cheese during incubation at 4°C (Trial 1).  
 
 
 
Figure 7.10 Behavior of E. coli O157:H7 in six formulations of low-moisture part-
skim (LMPS) mozzarella cheese during incubation at 4°C (Trials 2 and 3).  
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Figure 7.11 Behavior of E. coli O157:H7 in six formulations of low-moisture part-
skim (LMPS) mozzarella cheese during incubation at 12°C (Trial 1).  
 
 
 
 
Figure 7.12 Behavior of E. coli O157:H7 in six formulations of low-moisture part-
skim (LMPS) mozzarella cheese during incubation at 12°C (Trials 2 and 3).  
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7.5 Discussion 
In the first experimental trial, counts of all three organisms in all 
formulations tested initially decreased.  However, after the initial decrease 
Salmonella and E. coli O157:H7 counts recovered to the original inoculum levels 
after incubation at 4°C and increased at 12°C, while L. monocytogenes counts 
increased at both temperatures.  Salmonella and E. coli O157:H7 cannot grow at 
refrigeration temperatures.  The decline in cellular counts followed by an increase 
to initial inoculum levels suggest that SEA-i F75 initially injured cells and the 
injured cells were unable to grow on selective media and as cells of Salmonella 
and E. coli O157:H7 recovered, the growth of the recovered cells was detected 
through plating.  SEA-i F75 was not effective at inhibiting the growth of these 
organisms in low sodium LMPS mozzarella formulations.  Previous results in 
cheese agar showed that chloride could potentially be contributing to the function 
of SEA-i F75.  Therefore, low sodium LMPS mozzarella formulations could be 
lacking the amount of the chloride necessary to function for a prolonged period of 
time. 
In the second experimental trials, counts of all three organisms in treated 
samples steadily decreased over time.  However, since counts in control 
formulations also decreased, the reduction in counts cannot solely be attributed 
to the activity of SEA-i F75.  While reductions in pathogens were observed, there 
were high background counts of coliforms and psychrotrophs in all formulations.  
Competition with these spoilage organisms also could have potentially 
contributed to the reduction in pathogenic bacteria.  
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7.6 Conclusion 
 Though SEA-i F75 was the most effective antimicrobial during agar 
screenings, it was not effective at inhibiting the growth of Salmonella, E. coli 
O157:H7 and L. monocytogenes in low sodium LMPS mozzarella cheese 
formulations.  This study aimed to identify a suitable antimicrobial for use in a low 
sodium LMPS mozzarella cheese system. There has been an abundance of 
research done on antimicrobials and sodium replacement agents in cheddar and 
feta cheeses, but data regarding in mozzarella is limited; this study sought to 
provide data that would help to fill that gap.  Preliminary screening efforts yielded 
confidence that a lactoperoxidase-based antimicrobial would provide the best 
inhibition of pathogenic bacteria in low sodium LMPS mozzarella cheese.  
However, the results from the final study contradict that assumption.   
The decrease in efficacy of SEA-i F75 in the final cheese, from preliminary 
results in agar systems, could be attributed to several causes.  First, the poor 
microbial quality of the cheese used could have potentially overwhelmed the 
antimicrobial system.  Second, the lactoperoxidase system would not have been 
able to function optimally if there was no halide or thiocyanate present to promote 
its function.  Repeating the study and addressing these two issues could 
potentially provide different results and should be the focus of another study.  
Though the data from the final study does not provide much insight into which 
antimicrobial would work in a low sodium mozzarella system, data from 
preliminary screening can be used a starting point when trying to select an 
appropriate antimicrobial for a dairy system. Understanding the mechanisms and 
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limitations of different classes of antimicrobials is a valuable tool to employ 
before beginning any study.   
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8.0 Future Research 
   Future research includes attempting another challenge study using SEA-i 
F75 with cheese of better microbial quality and/or the addition of thiocyanate to 
promote the function of the lactoperoxidase system.   Additionally, the final 
cheese challenge study should be performed with one of the other three 
antimicrobials that showed promise in preliminary studies.  Changing the food 
matrix could potentially increase the efficacy of these antimicrobials.  
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Appendix: Final Cheese Challenge Tables 
Table A.1  Behavior of Listeria monocytogenes in artificially inoculated formulations of low-moisture part-skim (LMPS) mozzarella cheese made with and without sodium 
replacement agents and SEA-i F75 after incubation at 4° and 12°C (Trial 1). 
 L. monocytogenes Count (Log CFU/g) 
Pull Date Regular Sodium Low Sodium Untreated Low Sodium Treated NaCl/KCl Combination NaCl/Alta Combination NaCl/Salona Combination 
 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 
Day 0             
Replicate 1 3.60 3.60 3.45 3.45 3.36 3.36 3.10 3.10 3.06 3.06 3.05 3.05 
Replicate 2 3.69 3.69 3.57 3.57 3.54 3.54 3.16 3.16 3.01 3.01 3.15 3.15 
Replicate 3 3.59 3.59 3.64 3.64 3.13 3.13 3.46 3.46 3.04 3.04 3.25 3.25 
Average 3.62 3.62 3.55 3.55 3.34 3.34 3.24 3.24 3.04 3.04 3.15 3.15 
Day 1             
Replicate 1 3.01 3.29 3.26 3.71 2.93 2.97 3.19 3.13 3.58 3.45 3.29 2.95 
Replicate 2 3.45 3.83 3.01 3.90 3.27 2.99 3.08 3.18 3.10 3.38 3.10 3.35 
Replicate 3 3.60 3.64 3.25 3.72 3.12 3.20 3.77 3.10 3.51 3.43 3.01 2.88 
Average 3.35 3.59 3.17 3.78 3.11 3.05 3.35 3.14 3.40 3.42 3.13 3.06 
Day 3             
Replicate 1 NT1 3.54 NT 4.26 NT 4.22 NT 2.59 NT 3.45 NT 3.19 
Replicate 2 NT 3.32 NT 4.52 NT 4.15 NT 2.71 NT 3.68 NT 3.37 
Replicate 3 NT 3.59 NT 4.05 NT 4.61 NT 2.69 NT 3.44 NT 3.67 
Average NT 3.48 NT 4.28 NT 4.33 NT 2.66 NT 3.52 NT 3.41 
Day 7             
Replicate 1 3.19 6.31 3.63 6.14 2.62 4.28 3.04 4.89 2.60 5.50 2.94 4.52 
Replicate 2 3.37 6.60 3.69 6.23 2.72 4.76 2.95 5.04 2.43 5.53 3.01 4.25 
Replicate 3 3.76 6.18 3.45 5.61 3.01 4.36 2.72 4.61 1.76 5.45 2.89 4.64 
Average 3.44 6.36 3.59 5.99 2.78 4.47 2.90 4.85 2.26 5.50 2.95 4.47 
Day 15             
Replicate 1 5.98 6.92 5.05 6.48 4.30 6.88 3.94 6.19 5.68 6.35 5.26 7.04 
Replicate 2 5.78 6.96 4.91 6.45 4.38 6.31 4.68 6.06 5.66 7.28 4.33 5.69 
Replicate 3 5.77 6.94 5.42 7.10 4.57 5.70 5.04 5.72 5.58 6.99 5.10 6.17 
Average 5.84 6.94 5.13 6.67 4.42 6.30 4.55 5.99 5.64 6.87 4.90 6.30 
Day 35             
Replicate 1 6.70 7.61 6.16 6.60 5.41 6.66 5.06 6.29 6.90 7.77 7.19 7.62 
Replicate 2 6.99 7.11 6.05 7.20 5.12 6.68 4.86 6.50 6.83 7.73 6.07 7.56 
Replicate 3 7.24 7.55 5.89 6.76 5.56 6.95 6.21 6.72 6.19 7.40 5.30 7.79 
Average 6.98 7.42 6.03 6.86 5.37 6.77 5.38 6.50 6.64 7.63 6.19 7.66 
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Table A.2 Behavior of L. monocytogenes in artificially inoculated formulations of low-moisture part-
skim (LMPS) mozzarella cheese made with and without sodium replacement agents and SEA-i 
F75 after incubation at 4°C (Trials 2 and 3). 
 L. monocytogenes Count (Log CFU/g) 
Pull Date 
Regular 
Sodium 
Low Sodium 
Untreated 
Low Sodium 
Treated 
NaCl/KCl 
Combination 
NaCl/Alta 2345 
Combination 
NaCl/Salona 
Combination 
       
Day 0       
Replicate 1 2.92 3.09 2.99 2.02 3.19 2.93 
Replicate 2 3.09 3.01 3.14 2.00 2.68 2.98 
Replicate 3 3.09 2.96 2.84 1.48 3.00 3.09 
Replicate 4 3.04 2.90 3.16 3.01 2.99 3.13 
Replicate 5 3.02 3.06 2.99 3.17 2.97 3.07 
Replicate 6 3.04 3.00 3.06 3.06 2.85 0.70 
Average 3.04 3.01 3.04 2.81 2.97 2.97 
       
Day 1       
Replicate 1 2.81 2.98 3.05 1.60 2.79 2.76 
Replicate 2 2.67 2.94 3.14 2.00 2.82 2.88 
Replicate 3 2.92 2.90 2.97 1.48 2.68 3.05 
Replicate 4 2.76 3.12 2.92 2.83 2.19 2.89 
Replicate 5 2.90 2.71 2.80 2.76 2.37 2.70 
Replicate 6 2.94 2.87 2.78 2.55 2.51 2.88 
Average 2.84 2.94 2.96 2.48 2.61 2.88 
       
Day 7       
Replicate 1 2.94 3.38 2.70 0.70 1.65 2.10 
Replicate 2 2.69 2.93 2.75 1.60 2.16 2.81 
Replicate 3 2.92 2.74 2.69 1.54 1.78 2.19 
Replicate 4 2.41 2.22 <1 1.93 1.60 1.70 
Replicate 5 2.35 2.06 1.61 1.48 1.40 1.40 
Replicate 6 2.56 2.08 1.88 2.15 1.40 1.18 
Average 2.70 2.85 2.45 1.75 1.75 2.23 
       
Day 15       
Replicate 1 2.81 2.67 2.83 <1 2.41 2.53 
Replicate 2 2.74 2.62 2.79 <1 2.13 2.51 
Replicate 3 2.69 2.77 2.77 <1 2.08 2.53 
Replicate 4 2.43 2.35 2.11 2.02 1.00 1.54 
Replicate 5 2.44 2.10 2.08 1.40 0.70 1.95 
Replicate 6 2.23 2.23 2.36 1.88 <1 1.81 
Average 2.60 2.52 2.60 1.53 1.95 2.30 
       
 
 
 
 
 
 
 
 
 
 128 
 
Table A.3 Behavior of L. monocytogenes in artificially inoculated formulations of low-moisture part-
skim (LMPS) mozzarella cheese made with and without sodium replacement agents and SEA-i 
F75 after incubation at 12° (Trials 2 and 3). 
 L. monocytogenes Counts (Log CFU/g)  
Pull Date 
Regular 
Sodium 
Low Sodium 
Untreated 
Low Sodium 
Treated 
NaCl/KCl 
Combination 
NaCl/Alta 2345 
Combination 
NaCl/Salona 
Combination 
       
Day 0       
Replicate 1 2.92 3.09 2.99 2.02 3.19 2.93 
Replicate 2 3.09 3.01 3.14 2.00 2.68 2.98 
Replicate 3 3.09 2.96 2.84 1.48 3.00 3.09 
Replicate 4 3.04 2.90 3.16 3.01 2.99 3.13 
Replicate 5 3.02 3.06 2.99 3.17 2.97 3.07 
Replicate 6 3.04 3.00 3.06 3.06 2.85 0.70 
Average 3.04 3.01 3.04 2.81 2.97 2.97 
       
Day 1       
Replicate 1 3.04 3.10 3.04 2.06 2.64 2.78 
Replicate 2 2.89 2.85 2.45 2.00 2.55 2.54 
Replicate 3 3.16 2.96 2.82 2.18 2.55 2.62 
Replicate 4 2.62 2.60 2.60 1.40 2.27 2.79 
Replicate 5 2.72 2.47 2.60 2.82 1.98 2.62 
Replicate 6 2.84 2.65 2.82 2.80 2.24 2.54 
Average 2.92 2.83 2.76 2.45 2.43 2.66 
       
Day 3       
Replicate 1 2.62 2.15 1.60 1.54 1.85 2.89 
Replicate 2 2.36 2.51 2.35 1.40 1.98 2.77 
Replicate 3 2.61 2.54 2.44 1.00 1.54 2.62 
Replicate 4 3.07 3.50 3.26 2.55 2.54 2.82 
Replicate 5 2.90 2.59 2.87 2.80 2.77 3.00 
Replicate 6 2.94 2.95 2.69 1.74 2.82 3.07 
Average 2.81 2.94 2.78 2.27 2.48 2.89 
       
Day 7       
Replicate 1 3.59 3.18 2.71 2.11 2.22 2.39 
Replicate 2 2.87 3.13 2.76 1.95 1.70 2.55 
Replicate 3 2.82 3.21 2.59 0.70 1.74 2.62 
Replicate 4 2.94 3.35 1.54 1.48 1.40 1.48 
Replicate 5 2.72 3.49 1.60 1.00 <1 1.54 
Replicate 6 2.18 3.95 1.65 0.70 1.18 1.40 
Average 3.06 3.50 2.42 1.65 1.71 2.28 
       
Day 15       
Replicate 1 2.77 2.59 2.72 <1 1.98 2.00 
Replicate 2 3.02 2.42 2.45 <1 1.60 2.04 
Replicate 3 2.90 2.33 2.83 <1 1.74 1.48 
Replicate 4 1.98 1.95 1.30 1.30 <1 <1 
Replicate 5 1.60 1.98 1.00 <1 0.70 0.70 
Replicate 6 2.89 2.34 1.98 1.54 1.18 1.18 
Average 2.74 2.33 2.43 0.96 1.54 1.64 
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Table A.4  Behavior of Salmonella in artificially inoculated formulations of low-moisture part-skim (LMPS) mozzarella cheese made with and without sodium replacement agents 
and SEA-i F75 after incubation at 4° and 12°C (Trial 1). 
 Salmonella Count (Log CFU/g) 
Pull Date Regular Sodium Low Sodium Untreated Low Sodium Treated NaCl/KCl Combination NaCl/Alta Combination NaCl/Salona Combination 
 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 
Day 0             
Replicate 1 2.13 2.13 2.45 2.45 3.30 3.30 2.04 2.04 2.65 2.65 2.02 2.02 
Replicate 2 2.06 2.06 2.22 2.22 3.39 3.39 2.26 2.26 2.51 2.51 2.26 2.26 
Replicate 3 2.23 2.23 2.61 2.61 3.41 3.41 2.67 2.67 2.48 2.48 2.02 2.02 
Average 2.14 2.14 2.43 2.43 3.37 3.37 2.32 2.32 2.55 2.55 2.10 2.10 
Day 1             
Replicate 1 1.98 1.54 1.88 1.85 <11 0.98 <1 1.30 1.48 1.00 2.13 1.60 
Replicate 2 1.93 1.78 1.00 1.70 1.48 1.00 1.40 0.98 2.30 2.53 2.28 1.39 
Replicate 3 2.04 1.65 1.30 1.78 1.40 1.60 <1 1.00 1.85 2.51 0.95 2.53 
Average 1.98 1.66 1.39 1.77 1.26 1.19 0.97 1.09 1.87 2.01 1.79 1.84 
Day 3             
Replicate 1 NT 3.27 NT 2.94 NT <1 NT 2.39 NT <1 NT 1.93 
Replicate 2 NT 3.11 NT 3.73 NT 0.70 NT 2.18 NT 2.90 NT 3.13 
Replicate 3 NT 2.74 NT 3.25 NT 1.30 NT 0.98 NT 2.77 NT 2.79 
Average NT 3.04 NT 3.31 NT 0.63 NT 1.85 NT 2.19 NT 2.62 
Day 7             
Replicate 1 1.30 3.56 1.16 3.55 1.18 1.48 <1 1.16 1.48 3.51 1.00 2.64 
Replicate 2 1.30 4.22 2.04 3.22 <1 <1 <1 1.48 0.98 2.82 <1 2.33 
Replicate 3 1.54 3.55 1.30 3.59 <1 1.54 <1 0.95 0.95 3.71 <1 1.00 
Average 1.38 3.78 1.50 3.45 0.99 1.01 <1 1.20 1.14 3.35 0.83 1.99 
Day 15             
Replicate 1 1.18 2.72 2.06 3.83 0.70 2.47 <1 1.60 2.36 4.92 0.70 5.03 
Replicate 2 0.00 2.06 1.85 4.23 0.70 2.22 <1 1.40 1.90 3.84 <1 5.69 
Replicate 3 2.02 3.63 0.70 4.31 <1 <1 <1 2.74 1.48 4.03 <1 5.54 
Average 1.07 2.80 1.53 4.12 0.77 1.90 <1 1.91 1.91 4.26 0.83 5.42 
Day 35             
Replicate 1 2.23 5.05 2.54 5.47 1.48 3.12 <1 3.89 2.00 5.46 0.70 7.20 
Replicate 2 1.18 4.34 2.68 4.58 0.70 3.13 <1 2.98 4.12 5.22 1.78 6.85 
Replicate 3 2.67 4.25 2.11 4.76 1.30 2.97 <1 3.35 3.10 5.16 1.54 7.33 
Average 2.02 4.55 2.44 4.94 1.16 3.07 <1 3.41 3.07 5.28 1.34 7.13 
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Table A.5 Behavior of Salmonella in artificially inoculated formulations of low-moisture part-skim 
(LMPS) mozzarella cheese made with and without sodium replacement agents and SEA-i F75 after 
incubation at 4°C (Trials 2 and 3). 
Pull Date 
Regular 
Sodium 
Low Sodium 
Untreated 
Low Sodium 
Treated 
NaCl/KCl 
Combination 
NaCl/Alta 2345 
Combination 
NaCl/Salona 
Combination 
       
Day 0       
Replicate 1 2.72 2.56 1.85 1.54 1.98 2.10 
Replicate 2 2.56 2.66 1.81 1.54 1.81 1.78 
Replicate 3 2.59 2.89 2.06 2.11 1.95 2.08 
Replicate 4 2.10 2.65 2.35 2.24 1.18 2.20 
Replicate 5 2.38 2.86 2.23 2.69 1.93 2.22 
Replicate 6 2.41 2.44 2.63 2.37 2.00 2.22 
Average 2.50 2.71 2.25 2.26 1.88 2.12 
       
Day 1       
Replicate 1 2.31 1.00 1.18 1.65 1.30 2.10 
Replicate 2 0.70 1.00 <1 1.85 1.30 2.81 
Replicate 3 1.81 <1 <1 0.70 <1 2.19 
Replicate 4 1.18 1.74 1.40 1.40 1.98 1.93 
Replicate 5 1.48 2.27 2.22 0.70 0.70 1.54 
Replicate 6 1.70 2.49 2.45 0.95 1.48 1.30 
Average 1.79 1.98 1.91 1.42 1.45 2.25 
       
Day 7       
Replicate 1 <1 <1 0.70 <1 <1 <1 
Replicate 2 0.70 <1 <1 0.70 <1 <1 
Replicate 3 1.18 <1 <1 0.70 <1 <1 
Replicate 4 1.54 1.81 1.81 <1 <1 1.65 
Replicate 5 0.70 1.70 <1 1.00 1.65 0.70 
Replicate 6 1.40 1.54 <1 0.70 0.70 1.18 
Average 1.15 1.40 1.07 0.62 0.92 1.03 
       
Day 15       
Replicate 1 <1 <1 1.00 <1 <1 <1 
Replicate 2 <1 <1 <1 <1 <1 <1 
Replicate 3 <1 <1 <1 <1 <1 <1 
Replicate 4 <1 1.18 <1 <1 <1 <1 
Replicate 5 1.30 0.70 <1 <1 <1 <1 
Replicate 6 1.00 0.70 <1 <1 <1 <1 
Average 0.70 0.62 0.22 <1 <1 <1 
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Table A.6 Behavior of Salmonella in artificially inoculated formulations of low-moisture part-skim 
(LMPS) mozzarella cheese made with and without sodium replacement agents and SEA-i F75 after 
incubation at 12°C (Trials 2 and 3).  
Pull Date 
Regular 
Sodium 
Low Sodium 
Untreated 
Low Sodium 
Treated 
NaCl/KCl 
Combination 
NaCl/Alta 2345 
Combination 
NaCl/Salona 
Combination 
       
Day 0       
Replicate 1 2.72 2.56 1.85 1.54 1.98 2.10 
Replicate 2 2.56 2.66 1.81 1.54 1.81 1.78 
Replicate 3 2.59 2.89 2.06 2.11 1.95 2.08 
Replicate 4 2.10 2.65 2.35 2.24 1.18 2.20 
Replicate 5 2.38 2.86 2.23 2.69 1.93 2.22 
Replicate 6 2.41 2.44 2.63 2.37 2.00 2.22 
Average 2.50 2.71 2.25 2.26 1.88 2.12 
       
Day 1       
Replicate 1 <1 1.30 1.30 1.78 0.70 <1 
Replicate 2 0.70 <1 1.40 0.70 1.30 1.00 
Replicate 3 1.30 0.70 1.48 1.18 <1 <1 
Replicate 4 2.30 2.30 1.18 2.04 <1 1.74 
Replicate 5 2.10 2.24 1.54 1.81 <1 1.40 
Replicate 6 2.34 2.42 1.74 1.48 1.65 1.78 
Average 1.98 2.04 1.48 1.68 1.07 1.40 
       
Day 3       
Replicate 1 2.08 1.93 1.93 1.88 <1 2.39 
Replicate 2 1.74 2.16 2.16 1.40 1.40 2.55 
Replicate 3 1.93 2.06 2.06 0.70 0.70 2.62 
Replicate 4 3.10 2.89 2.36 2.11 <1 1.93 
Replicate 5 3.00 2.72 2.40 1.78 2.23 2.34 
Replicate 6 3.13 2.93 2.47 1.30 1.74 2.32 
Average 2.49 2.45 2.27 1.72 1.75 2.41 
       
Day 7       
Replicate 1 1.00 0.70 <1 <1 <1 <1 
Replicate 2 <1 1.48 1.18 <1 1.00 <1 
Replicate 3 1.00 <1 <1 1.00 1.18 <1 
Replicate 4 2.10 2.62 1.48 <1 0.70 1.65 
Replicate 5 2.19 1.00 1.00 0.70 1.48 1.30 
Replicate 6 2.23 1.40 1.65 0.70 1.00 1.65 
Average 1.89 1.91 1.22 0.52 1.07 1.26 
       
Day 15       
Replicate 1 0.70 <1 <1 <1 <1 <1 
Replicate 2 <1 <1 1.18 <1 <1 <1 
Replicate 3 <1 <1 <1 <1 <1 <1 
Replicate 4 1.88 <1 <1 <1 <1 <1 
Replicate 5 1.65 <1 <1 <1 <1 <1 
Replicate 6 <1 <1 <1 <1 <1 <1 
Average 1.32 <1 0.40 <1 <1 <1 
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Table A.7  Behavior of E. coli O157:H7 in artificially inoculated formulations of low-moisture part-skim (LMPS) mozzarella cheese made with and 
without sodium replacement agents and SEA-i F75 after incubation at 4° and 12°C (Trial 1). 
 E. coli O157:H7 Count (Log CFU/g) 
Pull Date Regular Sodium Low Sodium Untreated Low Sodium Treated NaCl/KCl Combination NaCl/Alta Combination NaCl/Salona Combination 
 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 4°C 12°C 
Day 0             
Replicate 1 3.27 3.27 3.53 3.53 2.26 2.26 3.45 3.45 3.22 3.22 2.68 2.68 
Replicate 2 3.51 3.51 3.67 3.67 2.11 2.11 3.45 3.45 3.10 3.10 2.45 2.45 
Replicate 3 3.72 3.72 3.47 3.47 2.06 2.06 3.64 3.64 3.01 3.01 2.98 2.98 
Average 3.50 3.50 3.56 3.56 2.14 2.14 3.51 3.51 3.11 3.11 2.70 2.70 
Day 1             
Replicate 1 2.96 2.91 2.65 3.37 1.85 2.44 2.81 2.98 2.68 3.26 3.15 2.93 
Replicate 2 3.13 2.89 3.00 3.48 2.27 2.71 2.54 2.60 2.99 3.33 3.01 3.17 
Replicate 3 2.94 3.08 3.05 3.81 1.00 1.54 2.54 2.81 2.92 3.68 2.69 2.87 
Average 3.01 2.96 2.90 3.55 1.70 2.23 2.63 2.80 2.86 3.43 2.95 2.99 
Day 3             
Replicate 1 NT 3.46 NT 4.15 NT 2.45 NT 2.98 NT 3.96 NT 2.54 
Replicate 2 NT 3.05 NT 3.87 NT 3.01 NT 2.64 NT 3.82 NT 2.74 
Replicate 3 NT 3.75 NT 4.06 NT 1.81 NT 2.63 NT 3.98 NT 2.50 
Average NT 3.42 NT 4.03 NT 2.42 NT 2.75 NT 3.92 NT 2.59 
Day 7             
Replicate 1 1.95 4.54 2.60 4.59 <11 3.15 1.69 3.49 1.48 4.95 0.70 4.84 
Replicate 2 1.78 4.30 2.48 4.59 <1 2.81 0.98 3.68 0.98 5.32 0.70 4.42 
Replicate 3 1.98 4.25 2.19 4.72 1.74 3.56 2.78 3.21 1.48 4.45 0.70 4.68 
Average 1.90 4.36 2.42 4.63 1.18 3.17 1.82 3.46 1.31 4.91 0.70 4.65 
Day 15             
Replicate 1 3.81 4.42 3.57 6.10 0.70 5.18 2.63 4.11 4.61 6.95 1.40 7.04 
Replicate 2 1.30 4.57 3.95 5.48 1.70 4.05 1.00 4.11 5.12 6.95 1.98 6.33 
Replicate 3 1.54 4.10 3.60 5.88 0.70 5.25 2.59 5.00 2.35 6.33 1.48 5.59 
Average 2.22 4.37 3.71 5.82 1.03 4.82 2.07 4.40 4.03 6.74 1.62 6.32 
Day 35             
Replicate 1 4.18 3.00 4.42 7.25 1.70 5.14 0.70 5.17 2.00 6.29 3.77 6.45 
Replicate 2 3.36 3.30 3.70 7.09 1.70 5.13 <1 5.98 4.12 6.53 4.30 6.70 
Replicate 3 3.65 4.77 3.57 6.59 1.40 5.83 2.47 5.94 3.10 6.46 4.20 7.77 
Average 3.73 3.69 3.90 6.97 1.60 5.37 1.36 5.69 3.07 6.43 4.09 6.97 
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Table A.8 Behavior of E. coli O157:H7 in artificially inoculated formulations of low-moisture part-
skim (LMPS) mozzarella cheese made with and without sodium replacement agents and SEA-i 
F75 after incubation at 4°C (Trials 2 and 3). 
Pull Date 
Regular 
Sodium 
Low Sodium 
Untreated 
Low Sodium 
Treated 
NaCl/KCl 
Combination 
NaCl/Alta 2345 
Combination 
NaCl/Salona 
Combination 
       
Day 0       
Replicate 1 2.74 2.92 2.49 2.67 2.58 2.64 
Replicate 2 2.64 2.89 2.56 2.81 2.55 2.77 
Replicate 3 2.78 2.83 2.51 2.99 2.56 2.51 
Replicate 4 2.69 2.47 2.72 2.52 2.70 2.72 
Replicate 5 2.91 2.80 2.82 2.66 2.76 2.65 
Replicate 6 2.94 3.04 2.78 2.81 2.62 2.69 
Average 2.80 2.86 2.66 2.77 2.64 2.67 
       
Day 1       
Replicate 1 2.50 1.78 1.30 0.70 <1 1.85 
Replicate 2 2.32 1.85 0.70 1.18 0.70 1.74 
Replicate 3 2.88 1.70 1.00 1.18 1.70 1.30 
Replicate 4 1.95 2.15 1.65 2.34 2.30 2.04 
Replicate 5 2.00 1.98 1.81 2.34 1.98 1.93 
Replicate 6 2.10 2.22 1.54 2.29 2.23 1.95 
Average 2.43 1.99 1.48 2.05 1.94 1.86 
       
Day 7       
Replicate 1 2.77 2.74 2.13 1.18 <1 2.15 
Replicate 2 2.79 2.81 1.93 1.54 1.00 2.04 
Replicate 3 2.95 2.61 1.60 1.78 2.08 1.98 
Replicate 4 2.57 2.60 1.95 2.02 1.93 1.48 
Replicate 5 2.02 2.29 1.95 2.04 1.81 1.85 
Replicate 6 1.91 2.22 1.81 2.15 1.95 1.65 
Average 2.65 2.59 1.93 1.89 1.79 1.91 
       
Day 15       
Replicate 1 2.58 2.47 1.54 <1 0.70 <1 
Replicate 2 1.40 2.16 1.30 <1 0.70 1.65 
Replicate 3 1.65 2.47 1.70 <1 1.30 <1 
Replicate 4 1.70 2.59 0.70 2.11 1.93 2.37 
Replicate 5 1.81 2.83 1.48 1.54 1.00 1.18 
Replicate 6 1.70 1.85 0.70 1.18 1.54 1.30 
Average 2.01 2.49 1.38 1.48 1.43 1.72 
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Table A.9 Behavior of E. coli O157:H7 in artificially inoculated formulations of low-moisture part-
skim (LMPS) mozzarella cheese made with and without sodium replacement agents and SEA-i 
F75 after incubation at 12°C (Trials 2 and 3). 
Pull Date 
Regular 
Sodium 
Low Sodium 
Untreated 
Low Sodium 
Treated 
NaCl/KCl 
Combination 
NaCl/Alta 2345 
Combination 
NaCl/Salona 
Combination 
       
Day 0       
Replicate 1 2.74 2.92 2.49 2.67 2.58 2.64 
Replicate 2 2.64 2.89 2.56 2.81 2.55 2.77 
Replicate 3 2.78 2.83 2.51 2.99 2.56 2.51 
Replicate 4 2.69 2.47 2.72 2.52 2.70 2.72 
Replicate 5 2.91 2.80 2.82 2.66 2.76 2.65 
Replicate 6 2.94 3.04 2.78 2.81 2.62 2.69 
Average 2.80 2.86 2.66 2.77 2.64 2.66 
       
Day 1       
Replicate 1 1.90 2.08 1.48 2.27 2.83 1.70 
Replicate 2 1.00 2.11 1.60 2.39 1.98 2.10 
Replicate 3 2.53 2.15 1.40 2.41 2.24 1.95 
Replicate 4 2.15 1.81 1.18 1.18 1.00 2.11 
Replicate 5 2.29 1.54 1.54 1.54 1.40 1.74 
Replicate 6 2.45 1.81 1.74 1.70 1.48 1.48 
Average 2.24 1.97 1.52 2.12 2.23 1.90 
       
Day 3       
Replicate 1 2.08 2.30 0.70 2.11 0.70 2.60 
Replicate 2 1.74 1.70 1.40 2.02 1.60 1.90 
Replicate 3 1.93 2.69 1.48 2.47 1.65 2.33 
Replicate 4 3.10 2.62 1.95 <1 1.00 1.30 
Replicate 5 3.00 2.58 2.56 1.54 <1 1.00 
Replicate 6 3.13 2.45 2.35 2.18 <1 <1 
Average 2.81 2.48 2.09 2.08 1.22 2.08 
       
Day 7       
Replicate 1 2.79 1.65 2.43 1.70 1.40 1.54 
Replicate 2 3.06 1.85 2.11 2.18 1.70 1.90 
Replicate 3 3.53 1.65 1.54 2.18 1.54 2.36 
Replicate 4 2.13 1.95 1.74 <1 2.04 2.02 
Replicate 5 1.95 2.19 1.70 < 2.13 1.85 
Replicate 6 2.28 2.18 1.91 2.10 2.11 1.98 
Average 2.97 1.97 2.00 1.90 1.91 2.01 
       
Day 15       
Replicate 1 2.06 1.70 0.70 <1 <1 0.70 
Replicate 2 2.29 1.65 1.60 <1 1.00 1.18 
Replicate 3 1.95 2.29 <1 <1 1.48 1.65 
Replicate 4 1.70 2.67 2.04 1.30 1.30 1.40 
Replicate 5 1.54 2.32 1.65 <1 1.00 0.70 
Replicate 6 2.33 1.85 2.20 1.54 1.18 <1 
Average 2.07 2.24 1.78 0.96 1.15 1.20 
       
 
 
